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SUMMARY 
In recent years, G-protein coupled receptors (GPCRs) have become important drug targets, 
which makes elucidation of their molecular structure and functional domains increasingly 
important for designing new and better therapeutic agents. The Glucagon-Like Peptide-1 
receptor (GLP-1R) is a GPCR. Its endogenous agonist, Glucagon-Like Peptide-1 (GLP-1), has a 
number of physiological effects that contribute to reducing blood sugar and body weight. 
Therefore, GLP-1R has become a promising target for the treatment of type 2 diabetes (T2D). 
The overall purpose of the Ph.D. project has been to investigate how GLP-1R interacts with 
receptor agonists. The thesis includes four studies, which investigate different aspects of these 
interactions. The first study elucidates GLP-1 binding to the extracellular domain of GLP-1R 
(ECD) (Study I), whereas the second study identifies receptor domains important for small 
molecule-mediated activation of GLP-1R (Study II). A fully functional, cysteine-deprived and C-
terminally truncated GLP-1R is developed and characterised in Study III. In Study IV, a cAMP 
biosensor is used to investigate the cAMP kinetics of GLP-1R upon stimulation with different 
receptor agonists.  
Collectively, the work has contributed to a more detailed understanding of GLP-1R 
pharmacology in a number of ways. A crystal structure elucidated the molecular details of GLP-
1 binding to the ECD of GLP-1R and supported the existence of different binding modes of GLP-
1 and exendin-4. In addition, the work established that seven cysteine residues in GLP-1R and 
more than half of the C-terminal tail are not required for GLP-1 binding or function. Last but 
not least, site-directed mutagenesis identified receptor domains and specific residues involved 
in small molecule-mediated activation of GLP-1R. 
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DANSK RESUMÉ 
En del af de lægemidler, der er blevet fremstillet de seneste år er rettede mod G-protein 
koblede receptorer. For at kunne designe nye og bedre lægemidler er det derfor vigtigt at 
klarlægge den molekylære struktur og de funktionelle domæner i G-protein koblede 
receptorer. Glucagon-Lignende Peptid-1 receptoren (GLP-1R) er en G-protein koblet receptor. 
Den endogene agonist, Glucagon-Lignende Peptid-1 (GLP-1), har en række fysiologiske 
effekter, der bidrager til at reducere blodsukkeret samt kropsvægten. GLP-1R er derfor blevet 
en vigtig brik i behandlingen af type 2 diabetes. 
Det overordnede formål med Ph.D. projektet har været at undersøge hvordan GLP-1R 
interagerer med agonister. Afhandlingen indeholder fire studier, der hver især belyser 
forskellige aspekter af disse interaktioner. Det første studie viser, hvordan GLP-1 binder til det 
ekstracellulære domæne i GLP-1R (ECD) (Studie I), hvorimod det andet studie identificerer 
domæner i GLP-1R, der er vigtige for, at små molekyler kan aktivere receptoren (Studie II). En 
funktionel, cystein-fattig og C-terminalt forkortet GLP-1R bliver fremstillet og karakteriseret i 
Studie III. I Studie IV benyttes en cAMP biosensor til at undersøge GLP-1R’s cAMP kinetik efter 
stimulation med forskellige agonister.  
Arbejdet har på flere måder bidraget til en mere detaljeret forståelse af GLP-1R’s farmakologi. 
En krystalstruktur viste de molekylære detaljer i GLP-1 binding til det ECD af GLP-1R og 
understøttede teorien om, at GLP-1 og exendin-4 binder til receptoren på forskellige måder. 
Arbejdet fastslog desuden, at syv cysteiner i GLP-1R og mere end halvdelen af C-terminalen 
ikke er nødvendig for, at GLP-1 kan binde til- og aktivere receptoren. Sidst men ikke mindst 
blev mutagenese brugt til at identificere domæner og specifikke aminosyrer i receptoren, der 
er vigtige for, at små molekyler kan aktivere GLP-1R. 
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LIST OF STUDIES 
 
The thesis is based on four studies, which will be referred to by their Roman numbers in the 
text. 
 
Study I Crystal Structure of GLP-1 in Complex with the Extracellular Domain of 
the GLP-1 Receptor 
Underwood, C.R., Garibay, P., Knudsen, L. B., Hastrup, S., Peters, G. H., Rudolph, 
R., Reedtz-Runge, S., The Journal of Biological Chemistry, 2010, 258, 723-730. 
 
 
Study II Transmembrane α-helix 2 and 7 are Important for Small Molecule-
Mediated Activation of the GLP-1 Receptor 
Underwood, C. R., Knudsen, S. M., Wulff, B. S., Bräuner-Osborne, H., Lau, J., 




Study III Development of a Cysteine-deprived and C-terminally Truncated GLP-1 
Receptor 
Underwood, C. R., Knudsen, L. B., Garibay, P., Peters, G. H., Reedtz-Runge, S. 
(will be submitted to ‘Peptides’) 
 
 




In addition to the scientific work, this thesis contains a general introduction to diabetes and 
GLP-1, followed by a general introduction to the structure of GPCRs with special focus on 
family B receptors. The introduction is followed by the ‘Results and Discussion’ section, which 
contains the scientific work. The work included in Study I and II was published in 2010 and 
2011, respectively, and Study III will be submitted to ‘Peptides’ in the near future. The two 
papers and the manuscript are included in the thesis1, and are each preceded by a short 
introduction. Study IV contains unpublished data, but some of the results are included in a co-
authored paper that is currently in preparation. Concluding remarks are made at the end of the 
thesis.
                                          
1 The two published papers are reprinted in this thesis with permission from the publishers 
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GENERAL INTRODUCTION 
Type 2 diabetes 
Obesity and type 2 diabetes 
Numerous studies confirm that the prevalence of obesity has increased dramatically over the 
last three decades. Obesity has become one of the largest health challenges of the 21st 
century, affecting more than 500 million people worldwide (1). Overweight and obesity are 
major risk factors for chronic diseases like T2D ((2-4)), cardiovascular diseases ((3;5)), 
hypertension ((3;6)) and certain forms of cancer ((7-9)), which cause millions of deaths every 
year. However, obesity is a complex condition, and not everyone develops metabolic 
complications like insulin resistance and decreased insulin secretion, which can lead to T2D. It 
appears that the distribution of body fat plays a greater role in obesity-related complications 
than the total amount of body fat as such (10-12). There is now general agreement that a 
large amount of abdominal fat, in particular visceral fat, increases the risk of T2D (10;11;13). 
Obese subjects tend to have enlarged adipocytes (14), and enlarged adipocytes are resistant 
to the antilipolytic effects of insulin (15), which leads to higher concentrations of circulating 
free fatty acids (FFA). Elevated concentrations of FFA in plasma can lead to lipotoxicity (16), 
which can induce insulin resistance in muscle (17;18) and liver (19) as well as stimulate 
gluconeogenesis (20). Enlarged adipocytes do not only release FFA, they also release 
inflammatory cytokines such as tumour necrosis factor-alpha (TNF-α), interleukin (IL) 1, IL-6 
(21-23) and other adipose-related hormones like leptin and adiponectin (24). These signalling 
molecules are commonly known as “adipokines”, and together with FFA, they affect lipid 
metabolism and insulin sensitivity (25;26). Insulin resistance is the first step towards T2D. To 
deal with the increased demand for insulin, the β-cell is forced to enhance the secretion of the 
hormone. This β-cell compensation is initially successful and normal glucose levels are restored 
(27). For obesity and insulin resistance to be associated with T2D, β-cells must be unable to 
fully compensate for the decreased insulin sensitivity (28). Genetic factors (29;30) and age 
(31) seem to play an important part in the pathogenesis of T2D, as β-cell compensation fails in 
subjects that have “susceptible” islets as opposed to “robust” islets. In these subjects, the 
increased demand for insulin leads to β-cells dysfunction (32;33), which over time may result 
in blood glucose concentrations higher than normal, but lower than diabetes thresholds 
(prediabetes)2. Not everyone with prediabetes progresses to T2D. According to the American 
Diabetes Association (ADA), 5-10% of people with prediabetes develop T2D every year and up 
to 70% will eventually develop T2D (34). 
The incretin effect and its implication in type 2 diabetes 
In recent years, so-called incretin-based therapies have become available for the treatment of 
T2D. The “incretin effect” refers to the observation that insulin secretion increases 
substantially in response to orally ingested glucose compared to intravenous (IV) glucose 
administration (35). Two main incretin hormones have been identified, namely GLP-1 and 
glucose-dependent insulinotropic polypeptide (GIP) (36-38). GIP was first identified as an 
incretin in the 1970’s (39), and 10 years later, GLP-1 was identified as a product of the 
preproglucagon gene. In addition to glucagon, the preproglucagon gene was found to encode 
two related peptides named GLP-1 and GLP-2 (40). The two peptides were tested for their 
                                          
2 For a current definition of prediabetes, see (34).  
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ability to stimulate the release of insulin, but only GLP-1 was found to have insulinotropic 
activity (41). Human studies indicate that the overall incretin effect is reduced in people with 
T2D. This appears to be a result of decreased sensitivity to GIP, as GLP-1 but not GIP retains 
most of its insulinotropic activity in people with mild T2D (42). 
Synthesis and degradation of GLP-1 
A single gene encodes proglucagon in mammals, but tissue-specific posttranslational 
processing yields different peptides (43) (Figure 1). Proglucagon is processed by prohormone 
convertase PC1 into glicentin, oxyntomodulin, GLP-1 and GLP-2 in intestinal L-cells (44;45) 
(Figure 1). The full-length forms of GLP-1 (GLP-1(1-37)-OH and GLP-1(1-36)amide) are N-
terminally truncated in L-cells, which yields two equally active isoforms, GLP-1(7-37)-OH and 
GLP-1(7-36)amide (43;46). Small amounts of full-length GLP-1(1-36)amide have also been 
detected in human pancreatic α-cells (47), where proglucagon is predominantly processed to 
glucagon (43;48) (Figure 1). GLP-1 is also produced in nucleus tractus solitarius (NTS) 
neurons in the brainstem (49;50). 
 
 
Figure 1. Schematic presentation of the structure and alternative processing of proglucagon. The basic 
amino acids lysine (K) and arginine (R) are sites for enzymatic cleavage. Proglucagon is cleaved by prohormone 
convertases in α-cells in the pancreas and in L-cells in the small intestine. The major bioactive peptides formed by 
cleavage are shaded. tGLP-1: Truncated GLP-1. The figure is reprinted with permission from the publisher (51). 
The majority of L-cells are located in the distal part of the small intestine, yet, plasma levels of 
GLP-1 increase rapidly after food intake (52;53). In line with the role of GLP-1 as an incretin, 
oral ingestion but not IV administration of glucose increases the release of GLP-1 (53), and 
recently the same has been shown for oral ingestion versus IV administration of lipids (54). 
 8 
The rapid secretion of GLP-1 after food intake has encouraged the idea that nutrient ingestion 
alone does not stimulate the release of GLP-1. It has been shown in several studies that the 
vagus nerve may play an important role in the secretion of GLP-1 from L-cells (55;56). After 
the initial nutrient-stimulated rise in circulating levels of GLP-1, levels fall rapidly due to renal 
clearance and N-terminal degradation of the peptide by dipeptidyl peptidase IV (DPP-IV) (57-
59). DPP-IV-mediated cleavage of GLP-1 results in the formation of GLP-1(9-36)amide and 
GLP-1(9-37)-OH (57;60). The biological function of GLP-1(9-36)amide has been discussed 
over the years and research is still on-going. A few studies have suggested that GLP-1(9-
36)amide is an antagonist of GLP-1R (61;62), whereas other studies have suggested that the 
metabolite acts as a weak agonist of GLP-1R (63). However, it is important to notice that GLP-
1(9-36)amide has no effect on insulin secretion (64). The short half-life of native GLP-1 limits 
its therapeutic potential, so various strategies have been employed to extend the in vivo half-
life of this hormone.         
The therapeutic potential of GLP-1 receptor agonists 
Two GLP-1R agonists, exenatide and liraglutide, are marketed for treatment of T2D. Exenatide 
is a synthetic version of exendin-4, which is a peptide isolated from the venom of the lizard 
Heloderma suspectum (65). GLP-1 and exendin-4 are approximately 50% identical, and 
exendin-4 binds to- and activates GLP-1R with similar affinity and potency compared to GLP-1 
(66). The human half-life of exenatide is 2.4 hours (67) compared to 2-3 minutes for native 
GLP-1, which necessitates two daily injections of this drug. Liraglutide is an acylated albumin-
bound human GLP-1 analogue with a human half-life of 11-13 hours, which makes this drug 
suitable for once-daily administration (68). Hence, liraglutide and exenatide may be classified 
as long-acting and short-acting GLP-1R agonists, respectively (69). Both GLP-1 analogues 
possess the beneficial effects of native GLP-1 (Figure 2), although they may result in side 
effects such as nausea and diarrhea. However, these adverse effects are typically mild and 
subside after 4-8 weeks of treatment (70-74). 
Physiological and pharmacological effects of GLP-1R agonists 
The first studies of the physiological role of GLP-1 were performed in the mid-1980s, and used 
the full-length forms of GLP-1. The full-length peptides showed no biological activity, and a few 
years later, it was discovered that the full-length isoforms were N-terminally truncated 
(43;75). Most of the circulating GLP-1 is found in the GLP-1(7-36)amide form, but small 
amounts of GLP-1(7-37)-OH are also detectable (76). Today, it is evident that GLP-1 has 





Figure 2. Overview of the physiological and pharmacological actions of GLP-1R agonists. Most of the 
physiological actions of native GLP-1 (A) are also observed for short-acting GLP-1R agonists like exenatide (B) and 
long-acting GLP-1R agonists like liraglutide (C). The figure is reprinted with permission from the publisher (69). 
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The effect of GLP-1R agonists on blood glucose levels 
The first discovered physiological function of GLP-1 is insulin secretion from pancreatic β-cells, 
where GLP-1(7-37)-OH and GLP-1(7-36)amide are equally potent in stimulating glucose-
dependent insulin secretion (77;78). The insulinotropic action of GLP-1 on β-cells is attenuated 
when glucose levels fall, hence GLP-1 cannot induce severe hypoglycaemia. Not only does 
GLP-1 potentiate insulin secretion from β-cells, it also stimulates transcription of the proinsulin 
gene (79). In addition, GLP-1 inhibits the secretion of glucagon from pancreatic α-cells (80), 
which is probably mediated through the local release of somatostatin from δ-cells in the 
pancreas (80;81). In the fasting state, the insulin-stimulating- and glucagon-suppressing 
actions of GLP-1 appear to contribute almost equally to the reduction of blood glucose levels 
(82). Conversely, the delaying effect of GLP-1 on gastric emptying seems to account almost 
entirely for its postprandial control of blood glucose (83;84). GLP-1 inhibits gastric emptying 
(85;86), which in turn slows the entry of nutrients such as glucose into the circulation (84).  
GLP-1 analogues like liraglutide and exenatide also reduce blood glucose levels, but their 
modes of action differ due to their different pharmacokinetic profiles (Figure 2). Short-acting 
GLP-1R agonists like exenatide primarily reduce postprandial blood glucose levels by inhibiting 
gastric emptying (67;87), but these GLP-1 analogous have limited effect on fasting glucose 
levels (70;88). Long-acting GLP-1R agonists like liraglutide show no significant delay of gastric 
emptying (89;90), and as a consequence, these GLP-1 analogues have limited effect on 
postprandial glucose control (70). However, the long-acting GLP-1R agonists have a stronger 
effect on fasting glucose levels compared to their short-acting counterparts (70;88). Both 
short- and long-acting GLP-1R agonists reduce the secretion of glucagon from pancreatic α-
cells (69).        
 
The effect of GLP-1R agonists on body weight 
As mentioned, obesity is tightly linked to the development of T2D. GLP-1 has been shown to 
reduce body weight in numerous of studies, but the exact mechanism by which GLP-1 
influences food intake (and weight) is not fully understood. GLP-1 inhibits gastric emptying 
(85;86), which stimulates satiety. However, long-acting GLP-1R agonists cause a reduction in 
body weight that is comparable to that observed for short-acting GLP-1R agonists (70;88) 
even though the long-acting compounds have no significant effect on gastric emptying 
(89;90). Hence, the weight-reducing effect of native GLP-1 and GLP-1 analogues appears to be 
independent of gastric emptying (90), but may be a result of their actions in the central 
nervous system (CNS). One of the first studies that demonstrated GLP-1 action in CNS showed 
that intracerebroventricular (ICV) administration of GLP-1 decreased food intake in fasted rats. 
ICV injection of the specific GLP-1R antagonist, exendin-4(9-39), blocked the inhibitory effect 
of GLP-1 on food intake, indicating that the appetite-suppressing effect of ICV injected GLP-1 
is mediated by specific interactions with GLP-1Rs in the brain (91). Several studies have now 
demonstrated that multiple brain regions could be involved in transducing the appetite-
suppressing effect of GLP-1 (92-94).  
 
Additional biological effects of GLP-1R agonists 
Cardiovascular disease is one of the long-term complications of obesity and T2D. High affinity 
receptors for GLP-1 have been located in the heart (95;96), and administration of GLP-1 has 
been shown to improve cardiovascular functions. For example, GLP-1 has been shown to 
improve endothelial function in T2D patients with coronary heart disease (97), and GLP-1 also 
appears to improve left ventricular dysfunction in patients suffering from heart failure (98). In 
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addition, native GLP-1 as well as GLP-1 analogues have the beneficial effect of reducing 
systolic blood pressure (70-74). However, long-acting GLP-1R agonists also increase the heart 
rate by 2-5 beats per minute (bpm) (70;99), although the underlying mechanism is not yet 
fully understood. The augmented heart rate does not appear to cause increased incidents of 
cardiovascular events (100).  
In addition to the positive cardiovascular effects, GLP-1 has also shown promising proliferating 
effects on β-cells and neurons. Declining β-cell function is one of the hallmarks of T2D, and 
antidiabetic treatment often requires intensification as the disease progresses (101). Animal 
and in vitro studies indicate that GLP-1 increases β-cell mass through a combination of 
increased β-cell neogenesis and proliferation as well as reduced apoptosis (102-104). More 
importantly, GLP-1 appears to improve β-cell function in patients with T2D (105;106). The 
prevalence of Alzheimer’s disease is also increased in patients with T2D (107;108). GLP-1 
appears to have neuroprotective effects in CNS (109) as well as stimulate neurogenesis (110). 
Hence, GLP-1 may also turn out to be useful in the treatment of neurodegenerative diseases.  
G-protein coupled receptors 
General introduction to GPCRs 
The superfamily of GPCRs, also known as seven-transmembrane (7TM) receptors, constitutes 
one of the largest families of proteins in the human genome (111). GPCRs consist of an 
extracellular N-terminus, seven membrane-spanning α-helices connected by three extracellular 
and three intracellular loops, and an intracellular C-terminus (112). It is believed that all 
GPCRs share the same characteristic topology, as the receptors interact with a common 
intracellular repertoire of heterotrimeric GTP-binding proteins (G-proteins) (Figure 3). The 
structural variety among GPCRs is related primarily to a great diversity of ligands (ions, 
nucleosides, peptide hormones, glycoproteins, amino acids etc.). Ligand binding to a GPCR 
leads to conformational changes in the interior part of the TM domain, resulting in activation of 
specific G-proteins, which in turn activate downstream effector proteins such as adenylyl 
cyclase (AC), phospholipase C (PLC) and ion channels (Figure 3) (113). However, many GPCRs 
also exhibit more complex signalling behaviour like constitutive activity (114), biased 
agonism/functional selectivity (115;116) and G-protein-independent signalling (115;117).  
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Figure 3. Schematic representation of GPCR signal transduction pathways.  Agonist binding to a GPCR leads to 
conformational changes in the intracellular part of the TM domain, which enables binding of a heterotrimeric G-protein 
(α, β and γ subunit). GDP is exchanged for GTP in the α-subunit upon formation of the GPCR-G-protein complex, which 
leads to dissociation of the α-subunit from the βγ heterodimer. Depending on the isoform, the α-subunit as well as the 
βγ heterodimer regulate various effector proteins (113). cAMP: Cyclic adenosine monophosphate, DAG: Diacylglycerol, 
IP3: Inositol triphosphate. 
Family A GPCRs 
Based on protein sequence similarity, GPCRs can be divided into five families: Rhodopsin 
(family A), secretin (family B), glutamate (family C), adhesion and Frizzled/Taste 2 receptors 
(112). Family A is by far the largest and best characterised GPCR family. More than 85% of the 
human GPCRs are thought to belong to family A (112), which makes this family particularly 
interesting in terms of drug discovery and development. A prerequisite for designing new and 
improved drugs is to understand how different ligands interact with GPCRs and how these 
ligands control the equilibrium between active and inactive conformational states. X-ray 
crystallography is currently the most favoured technique for structural determination of GPCRs, 
as it can provide detailed information about specific receptor-ligand interactions and the 
conformational changes associated with GPCR activation. Hence, structural determination of 
GPCRs, in particular family A GPCRs, has progressed rapidly over the past 10 years and 
provided invaluable information about the molecular details of ligand binding and receptor 
activation.  
Until recently, the only known structure of a GPCR was that of bovine rhodopsin covalently 
bound to the chromophore 11-cis-retinal, which represents the ‘dark’ inactive state of the 
molecule (118). The crystal structure of rhodopsin completed decades of biochemical and 
biophysical work on the interrelationship of the seven α-helices in GPCRs (119-121). However, 
although representing family A GPCRs, bovine rhodopsin shows little sequence homology with 
other family A receptors. The first crystal structures of a typical family A GPCR were published 
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recently: The β2-adreneric receptor (β2AR) bound to the inverse agonist carazolol (122-124). 
These structures were soon succeeded by crystal structures of other ligand-activated family A 
GPCRs, all of which represented inactive conformations of the receptor in question (125;126). 
Recently, crystal structures of a thermostabilised avian β1-adreneric receptor (β1AR) coupled to 
two full agonists were published (127). However, the structures represented inactive states of 
the receptor, possibly due to six thermostabilising mutations that restricted the receptor in an 
inactive conformation. Simultaneously, a different research group published two crystal 
structures of agonist-bound β2AR, of which one represented an active conformation (128;129). 
It became clear that agonist binding in itself is not enough to stabilise β2AR in an active 
conformation. Stabilisation of the active state requires simultaneous binding of agonist and Gs, 
the stimulatory G-protein for AC (128).  Shortly after the release of the agonist-bound 
structures, a crystal structure of β2AR in complex with a nucleotide-free Gs-protein was 
published (130).      
 
Inactive versus active conformation of β2AR 
The crystal structures of β2AR in complex with the inverse agonist carazolol (122-124) were 
the first GPCR structures published since those of rhodopsin. Previous fluorescence resonance 
energy transfer (FRET) based studies had shown that the C-terminal and the third intracellular 
loop (ICL3) were the most unstructured regions of β2AR (131). The last 48 amino acids were 
removed from the C-terminal of β2AR (122;123), and two different approaches were employed 
to stabilise ICL3. The first approach used a monoclonal antibody (Mab5) that bound to ICL3 
(123). This stabilised the receptor enough to facilitate crystallisation, but the binding pocket 
was poorly resolved in the 3.4 Å resolution structure (123). The second approach replaced 
most of ICL3 with T4 lysozyme (T4L), which stabilised the receptor and resulted in a 2.4 Å 
resolution structure (122). 
The overall structure of β2AR is similar to that of rhodopsin with seven TM helices organised in 
a counter clockwise orientation as seen from the extracellular side of the membrane (Figure 
4A). In addition, an eighth helix resides parallel to the cytoplasmic face of the membrane. A 
similar helix is believed to exist in all family A GPCRs (132) and most likely also in some family 
B GPCRs (133;134). Transmembrane helix 2 (TM2), TM5, TM6 and TM7 are bent around Pro 
residues. Helix kinks induced by Pro residues are also observed in rhodopsin, and are thought 
to facilitate the structural changes involved in receptor activation (135). The second 
extracellular loop (ECL2) of β2AR contains a short α-helical segment, which is not observed in 
rhodopsin (Figure 4B). The rigid structure of ECL2 exposes the binding pocket of β2AR to 
solvent, despite the fact that it is buried between TM3, TM4, TM5 and TM7 (122).    
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Figure 4. Structure of the β2AR-T4L fusion protein (inactive β2AR structure). The receptor and T4L are 
coloured in grey and orange, respectively. (A) The overall structure of β2AR-T4L as viewed from the extracellular side 
of the plasmamembrane. (B) β2AR-T4L as viewed from the side. T4L is fused between the cytoplasmic ends of TM5 
and TM6, but in the crystal structure, T4L is tilted away from the receptor, resulting in limited contact between the two 
proteins (PDB ID: 2RH1). 
In an effort to crystallise the active conformation of β2AR, researchers identified a high affinity, 
slow off-rate agonist, BI-167107 (128). Two different approaches were employed to stabilise 
an active conformation of the receptor. Initially, the small antibody (nanobody) Nb80 was used 
as a surrogate for the Gs-protein, and the final structure contained BI-167107-bound β2AR-T4L 
in complex with Nb80 (128). Shortly after, BI-167107-bound β2AR-T4L was crystallised in 
complex with a nucleotide-free Gs-protein (130). Instead of replacing ICL3, T4L was now fused 
to the unstructured N-terminal domain of β2AR, and the complex was further stabilised with a 
nanobody (Nb35) bound to the Gαs-subunit. The overall structure of β2AR is very similar in the 
Nb80- and the Gs-coupled state (overall root mean square deviation ~ 0.6Å). More 
importantly, the two structures are very similar near the highly conserved E/DRY motif in the 
cytoplasmic end of TM3. The E/DRY sequence is found in ~70% of all family A GPCRs (124), 
and is thought to be important for maintaining the receptor in an inactive conformation (136). 
In the inactive state of rhodopsin, Glu134 and Arg135 of the ERY motif form hydrogen bonds and 
ionic interactions with Glu247 in the cytoplasmic end of TM6. This has been referred to as the 
“ionic lock”, as the lock is broken upon activation of rhodopsin (136). However, the two crystal 
structures of carazolol-bound β2AR agree that the ionic lock appears to be broken in the 
inactive state of β2AR (124), as Asp130 and Arg131 of the DRY motif interact primarily with each 
other rather than with Glu268 in TM6. In addition, the distance between TM3 and TM6 is greater 
than observed for rhodopsin, indicating that the ionic lock is not essential for maintaining an 
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inactive conformation of β2AR in the crystal. Comparison of the agonist- and carazolol-bound 
structures of β2AR reveals that the cytoplasmic ends of TM5 and TM6 move outwards upon 
agonist binding (130) (Figure 5A), which resembles the conformational changes observed for 
activation of rhodopsin (136). In addition, TM5 is extended with seven residues in the 
cytoplasmic end (Figure 5A). 
 
 
Figure 5. Conformational changes associated with agonist binding to β2AR. (A) Superposition of the β2AR-Gs 
structure (green, PDB ID: 3SN6) and the carazolol-bound β2AR structure (orange, PDB ID: 2RH1) as viewed from the 
cytoplasmic side of the plasmamembrane. The main rearrangements involve a 14 Å outward movement of TM6, as 
indicated with a yellow arrow, and an extension of TM5 by two helical turns (130). (B) Structure of the nucleotide-free 
β2AR-Gs complex (PDB ID: 3SN6). Gαs (red) is made up of two subdomains; a GTPase domain that interacts with β2AR 
and the β-subunit (αRas), and an α-helical domain (αAH). The interface between the two domains forms the nucleotide-
binding pocket, but in the nucleotide-free state, the αAH domain has a variable position relative to the rest of the 
complex (130). 
The crystal structure of Gs-coupled β2AR has for the first time uncovered the structure of an 
activated Gs-protein. Gs consists of three subunits, α, β and γ (Figure 5B). Gαs is made up of 
two subdomains, a GTPase domain that interacts with β2AR and the β-subunit (αRas), and an α-
helical domain (αAH). The interface between the two domains forms the nucleotide-binding 
pocket (130) (Figure 5B). In the agonist-bound state, β2AR does not interact with the β- or the 
γ-subunit of Gs. Instead, the active conformation of β2AR is stabilised by interactions between 
the αRas domain of Gs and ICL2, TM5, and TM6 of β2AR. Sequence alignment with other GPCRs 
indicates that there is no conserved motif for Gs-coupling. Only one amino acid, Phe139 in ICL2, 
which is partially conserved in other Gs-coupled receptors, interacts with Gαs.  
 16 
Family B GPCRs 
Family B of the GPCR superfamily was initially defined in 1991 by the cloning and expression of 
the rat secretin receptor (137). Subsequently, other family B receptors were cloned including 
the parathyroid hormone (PTH) receptor (138), the calcitonin receptor (139), the GIP receptor 
(GIP-R) (140), the corticotrophin-releasing factor (CRF) receptor (141), the vasoactive 
intestinal polypeptide (VIP) receptor (142), the pituitary adenylate cyclase-activating 
polypeptide (PACAP) type I receptor (143) and the glucagon receptor (GCGR) (144). The 
GCGR branch consists of GCGR, GLP-1R, GLP-2R and GIP-R. 
Family B GPCRs are characterised by a relatively large ECD of about 120-150 amino acid 
residues. The ECD is essential for peptide ligand binding, and the structural integrity of the 
ECD relies on three conserved disulphide bonds and several conserved residues, which will be 
described in detail in the following paragraph. The first crystal structure of a TM domain of a 
family B GPCR was solved recently. The N- and C-termini were deleted from the type-1 CRF 
receptor (CRFR1), and several thermostabilising mutations were introduced. These 
modifications facilitated crystallisation of the receptor, and the structure was solved to 2.6 Å 
resolution (145). As of December 2012, limited information is available on the structure itself, 
but it has been shown that the extracellular part of the TM domain adopts a much more open, 
V-shaped conformation compared to family A GPCRs. The open conformation of CRFR1 
probably represents the general structure of family B GPCRs, as this family of receptors binds 
large peptide ligands and have a large ECD. The intracellular part of the TM domain of CRFR1 
is strikingly similar to the intracellular part of family A GPCRs (145). This is not surprising as 
GPCRs of different families activate similar G-proteins. 
The crystal structure of CRFR1 most likely represents the antagonist-bound (inactive) state, 
and does not provide any information about peptide binding to the receptor. It is assumed that 
peptide ligands bind to family B GPCRs according to the two-domain model. This model 
suggests that the C-terminal part of the peptide binds the ECD of the receptor while the N-
terminal part of the peptide binds to the TM domain and extracellular loops (Figure 6). Ligand 
binding induces a conformational change that enables the intracellular segments of the 









Figure 6. A model for ligand binding to family B GPCRs. Peptide ligands are believed to bind to family B GPCRs 
according to the two-domain model. First, the C-terminal part of the ligand (red) binds the ECD of the receptor (dark 
green), followed by binding of the N-terminal part of the ligand (blue) to the TM receptor domain (light green). 
Structural rearrangements in the receptor activate the Gs-protein, leading to dissociation of the Gα subunit and 
formation of the second messenger cAMP. The figure is reprinted with permission from the publisher (147). 
 
The binding orientation of family B GPCR ligands was first acknowledged in studies of chimeric 
peptides and receptors (148-153). The two-domain model is also generally consistent with 
photoaffinity cross-linking studies of several family B GPCRs. Photoreactive side chains in the 
C-terminal part of the peptide ligand interact with residues in the ECD of the receptor, whereas 
photoreactive side chains in the N-terminal part of the ligand interact with the TM receptor 
domain upon exposure to UV-light (154-157). Most recently, substantial evidence for the two-
domain model has come from the structural characterisation of the isolated ECDs of several 
family B GPCRs. The first structure of an isolated ECD of a family B GPCR was solved  by 
nuclear magnetic resonance (NMR) spectroscopy (158). Subsequently, structures of ligand-
bound ECDs were solved including the ECD of CRFR1 (159), the type-1 PACAP receptor (PAC1-
R) (160), GIP-R (161), GLP-1R (162) and the type-1 PTH receptor (PTH-1R) (163). ECDs of 
family B receptors all share a common molecular architecture, termed the ‘secretin family 
recognition fold’ (164), which is described in detail in the following section.  
The crystal structure of CRFR1 is devoid of an ECD, so the orientation of the ECD relative to 
the TM domain is still unknown for family B GPCRs. However, a recent study identified blocking 
antibodies that bind to the ECD of GCGR (165). A combination of chimeric receptors and site-
directed mutagenesis led the authors to suggest that the ECD of GCGR may interact with ECL3 
in the absence of an agonist, which predominantly retains GCGR in an inactive conformation. 
Glucagon binding may uncouple the ECD from ECL3 and in this way stabilise an active receptor 
conformation (165). This inhibitory effect of the ECD has not (yet) been reported for other 
family B GPCRs. However, the ECD of GLP-1R has been implicated directly in receptor 
activation, as an endogenous agonist sequence, NRTFD, was proposed to exist in the ECD of 
GLP-1R (166). Interestingly, a photolabile benzoyl phenylalanine (Bpa) was recently 
introduced into the pentapeptide derived from this sequence. Photo-induced cross-linking 
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subsequently showed that NRTFD binds to ECL3 of GLP-1R (167), suggesting that the ECD and 
ECL3 may also be functionally coupled in GLP-1R.       
The Glucagon-Like Peptide-1 Receptor 
In the 1980’s, it was suggested that GLP-1 acts through specific receptors located on the 
surface of pancreatic β-cells, as high-affinity binding sites for GLP-1 (Kd = 200 pM) and 
activation of cAMP signal transduction (EC50 = 250 pM) were identified in insulinoma β-cell 
lines (168). The rat GLP-1R was cloned in 1992 from a rat pancreatic islet cDNA library (169) 
followed by cloning of the human GLP-1R in 1993 (170). Today, GLP-1Rs have been detected 
in several tissues including pancreas, lung, GI-tract, kidney, heart and brain (95).  
The GLP-1R consists of a predicted signal sequence, an ECD of approximately 120 residues, 
seven membrane-spanning α-helices connected by three extracellular and three intracellular 
loops (the TM domain), and a C-terminal intracellular tail. The ECD contains three disulphide 
bonds and three potential asparagine (N)-linked glycosylation sites (169). Inhibition of the 
glycosylation process with tunicamycin reduced the number of GLP-1 binding sites, indicating 
that glycosylation of GLP-1R ECD is important for receptor expression at the cell surface but 
not for ligand binding (171). 
 
The N-terminal Extracellular Domain 
The isolated ECD of GLP-1R can be expressed recombinantly in E. coli inclusion bodies and 
refolded to form a functional receptor domain (172-174). GLP-1 binds to the isolated ECD with 
reduced affinity (IC50 > 500 nM), compared to the full-length receptor (IC50 ~0.5 nM) 
(173;174), suggesting that additional binding determinants of GLP-1 are present in the TM 
domain in agreement with the two-domain binding model. Interestingly, exendin-4 and 
exendin-4(9-39) maintain high affinity for the isolated ECD (IC50 = 6 nM compared to IC50 
~0.5 nM for the full-length receptor) (173;174). The molecular details of GLP-1 binding to the 
ECD are described in Study I. 
The core structure of GLP-1R ECD represents the typical ‘secretin family recognition fold’ of 
family B GPCRs (Figure 7A) with an N-terminal α-helix (residues Leu32-Glu52) linked by a 
disulphide bond to a central core consisting of two regions of antiparallel β-sheets (β-strand 
β1-β4). Residues Thr65-Phe66 (β1) and Cys71-Trp72 (β2) constitute the first region of antiparallel 
β-sheets, and the second region is comprised of residues Gly78-Ser84 (β3) and His99-Thr105 (β4) 
(Figure 7A and B) (162). Six loop regions (L1-L6) are present between the α-helix and β-
strands. The tertiary structure is stabilised by three conserved disulphide bonds and by several 
intramolecular interactions (162). The α-helix is connected to β2 through a disulphide bond 
between Cys46 and Cys71 (Figure 8A). The α-helix also interacts with β1, as the side chain of 
Arg64 (β1) forms hydrogen bonds with the backbone of Leu50, Asp53 and Pro54 (Figure 8A). The 
two regions of antiparallel β-sheets are joined by the disulphide bond between Cys62 (before 
β1) and Cys104 (β4). The last disulphide bond connects the end of β3 (Cys85) to a small α-helical 
segment in the C-terminal part of the ECD (Cys126) (162). 
In addition to the three disulphide bonds, six residues are conserved in the ECD of all family B 
GPCRs (Asp67, Trp72, Pro86, Arg102, Gly108 and Trp110 in GLP-1R) and they are important for the 
tertiary structure (162) (Figure 8B). The carboxyl group of Asp67 stabilises the turn between β1 
and β2 through hydrogen bonds with the backbone nitrogens of Tyr69 and Ala70. In addition, 
the carboxyl group of Asp67 forms hydrogen bonds with the side chain nitrogens of Arg102 on β4 
and Trp72 on β2. Arg102 is aligned between the side chains of Trp72 and Trp110 forming a central 







Figure 7. The ECD of GLP-1R. (A) Ribbon representation of the structure of GLP-1R ECD (α-helix in black, β-strands 
in red and loops in grey). Disulphide bonds are shown as orange sticks, and loop regions L1-L6 are indicated. Residues 
Thr65-Phe66 (β1) and Cys71-Trp72 (β2) constitute the first region of antiparallel β-sheets, and the second region is 
comprised of residues Gly78-Ser84 (β3) and His99-Thr105 (β4). (B) Sequence of GLP-1R ECD (residues 1-145). Residues 
shown in bold form the ligand binding site, and the secondary structure is depicted in the panel above the sequence. 
The predicted signal sequence is indicated by a grey rectangle, α-helical segments are shown as helixes and β-strands 






Figure 8. Intramolecular interactions of the GLP-1R ECD. (A) Stick representation of the disulphide bond 
between Cys46 on the α-helix (black) and Cys71 on β2 (red) and the interactions of the guanidine group of Arg64 with 
Leu50, Asp53, Pro54 and Asp74. (B) Stick representation of the residues Asp67, Tyr69, Ala70, Trp72, Arg102 and Trp110 (147). 
PDB ID: 3IOL.  
Structural differences between the ECDs of GLP-1R, GIP-R and GCGR 
Crystal structures of the ECDs of GLP-1R, GIP-R and GCGR are now available. The ECDs of 
GLP-1R and GIP-R have been crystallised in complex with their endogenous peptide ligands 
(161;175), but efforts to crystallise the glucagon-bound ECD of GCGR have so far been 
unsuccessful. However, GCGR ECD was recently crystallised in complex with the Fab fragment 
of a blocking antibody, mAb1 (165). The crystal structure revealed that mAb1 inhibits glucagon 
binding to the ECD by occupying a surface that covers the binding pocket.   
The ECD of GLP-1R shares 34% and 46% sequence identity with the ECDs of GIP-R and GCGR, 
respectively, and the tertiary structure of the three ECDs is very similar (Figure 9A). However, 
small structural differences are observed in the N-terminal α-helix and in loop region L6, which 
may contribute to ligand specificity. The most noticeable difference between the three 
structures is observed for the conformation of loop L6. GLP-1R and GCGR contain an additional 
loop (L6), which is not observed in the ECD of GIP-R. In addition, the conformation of L6 is 
different in GLP-1R compared to GCGR, which Koth et al. explained by an additional amino acid 
(Leu118) in GLP-1R compared to GCGR. However, as illustrated in Figure 9B, direct interactions 
between residues in L6 of GCGR ECD and residues in the Fab fragment of mAb1 may better 
explain the altered conformation of loop L6. In addition, Koth et al. explained the structural 
difference between the N-terminal α-helices of GCGR and GLP-1R by the presence of an 
additional residue, Phe33, in the α-helix of GCGR ECD. However, as illustrated in Figure 9B, 
packing interactions between a symmetry-related Fab fragment and residues in the N-terminal 





Figure 9. Structural differences between the ECDs of GLP-1R, GIP-R and GCGR. (A) The tertiary structure of 
GLP-1R ECD (grey, PDB ID: 3IOL) is highly similar to that of GIP-R (green, PDB ID: 2QKH) and GCGR (red, PDB ID: 
4ERS). However, structural differences are observed in the N-terminal α-helix and in loop region L6. (B) Some of the 
interactions between residues in the ECD of GCGR (red) and residues in the Fab fragment of mAb1 (purple). The 
guanidine groups of Arg108 and Arg111 in the ECD of GCGR interact with the backbone carbonyl of Ser270 and the 
carboxyl group of Glu313, respectively, in the Fab fragment of mAb1. A hydrogen bond between Asp30 in the ECD of 
GCGR and Arg233* in a symmetry-related Fab fragment (dark green) is also shown. 
The transmembrane and C-terminal domain 
Chimeric receptor studies and site-directed mutagenesis have been employed to characterise 
determinants of ligand binding and activation in the TM domain, loops and C-terminal tail of 
GLP-1R. A pair of polar residues in TM2 is a conserved feature among family B GPCRs, and 
they appear to be important for agonist binding and activation of several family B receptors 
(152;176;177). Neighbouring Arg and Ser residues make up a polar face of TM2 of GLP-1R 
(Figure 10), which may provide a surface for interaction with either GLP-1 or another TM helix 
during receptor activation. The latter is supported by site-directed mutagenesis studies on the 
PTH receptor, which suggest that Arg190 in TM2 could be functionally linked to Gln394 in TM7 
(Figure 10) (178). In addition, an Arg190-Ala mutation in GLP-1R reduced agonist- as well as 
antagonist affinity, suggesting that Arg190 is important for the general structure of the receptor 
rather than GLP-1 binding (179).  It appears that polar residues in the TM domain are 
important for GLP-1 binding, as polar residues (Lys197, Asp198, Lys202, Asp215 and Arg227, Figure 
10) in ECL1 and one polar residue in TM4 (Lys288) probably contribute to the binding 
determinants of GLP-1R (180;181). However, nonpolar residues may also be involved in 
binding of GLP-1 to ECL1, as substitution of Met204 and Tyr205 with Ala (Figure 10) markedly 
reduced the affinity of GLP-1 (182). A disulphide bond connecting ECL1 and ECL2 seems to be 
a conserved feature among family A and family B GPCRs (125;183-185). Mutational studies on 
the VIP receptor suggest that this linkage is essential for high affinity ligand binding, possibly 
by stabilising an active receptor conformation (185). Similar observations were made for PTH-
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1R, where mutation of Cys281 and/or Cys351  to serine reduced ligand binding and receptor 
expression levels (186). Mutational studies of GLP-1R suggest that a disulphide bond between 
ECL1 and ECL2 is not essential for GLP-1 binding, but ECL2 is probably positioned close to the 
binding pocket of the receptor (187). The importance of ECL2/TM5 in GLP-1 binding is further 
supported by two independent Ala-scans of this region (187;188). Taken together, residues in 
the loops and in the extracellular end of the TM-helices appear to be important for GLP-1 
binding, but to less extent for binding of exendin-4 (182;189). Subtle differences in the 
binding modes to the TM domain may explain why the two ligands bind to the full-length GLP-
1R with similar affinity despite the differential affinity for the isolated ECD. The existence of 
differences in the binding modes of GLP-1 and exendin-4 to the GLP-1R TM domain is also 
supported by the observation that N-terminal truncation of exendin-4 by two amino acids 
generates a high affinity antagonist (63). This is not observed for N-terminal truncation of 
GLP-1 (63).  
 
 
Figure 10. Snake diagram of the TM domain, loops and C-terminal tail of GLP-1R. Residues in the TM domain, 
which are experimentally determined to be important for peptide ligand binding and/or activation of the receptor are 
shown as white letters in black circles. Residues thought to be important for Gs-protein coupling are shown as black 
letters in grey circles and serine doubles involved in desensitisation and internalisation of the receptor are shown as 
grey letters in black circles. The putative disulphide bond that connects ECL1 and ECL2 is indicated with a dashed line.  
Long before GLP-1R was cloned, it was recognised that GLP-1 increases the production of cAMP 
in islet cell lines (79;168). Shortly after the rat GLP-1R was cloned, it was shown that 
activation of the receptor leads to activation of AC and PLC, which increases cellular 
concentrations of cAMP and Ca2+, respectively (190). It is now well established that GLP-1R 
can signal through multiple G-protein signalling pathways-at least in some cell lines. GLP-1R 
can couple to Gsα, Gqα and Giα in Chinese hamster ovary (CHO) cells (191), depending on the 
ligand (functional selectivity). In addition, GLP-1R can signal independently of G-proteins, that 
is, the receptor can activate the mitogen-activated protein (MAP) kinase pathway, leading to 
phosphorylation of extracellular signal-regulated kinases 1 and 2 (ERK1/2) through the 
recruitment of β-arrestins (192;193). The receptor preferably couples to Gsα (194), and the 
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subsequent rise in cAMP levels has a direct effect on insulin secretion (79). Oxyntomodulin is a 
37 amino acid peptide that contains the sequence of glucagon followed by a C-terminal 
extension of 8 amino acids (Figure 1). Oxyntomodulin acts as a full agonist of GLP-1R in 
mediating a cAMP response (195), but as a partial agonist in mediating a Ca2+ response in 
CHO cells (194) and in recruitment of β-arrestins to GLP-1R in human embryonic kidney (HEK) 
cells (195). Specific determinants for the coupling of GLP-1R to Gs are thought to be located 
mainly in the cytoplasmic end of TM5 and in the N-terminal part of ICL3 (Figure 10). Mutation 
of hydrophobic residues in the cytoplasmic end of TM5 (Val327, Ile328) and in ICL3 (Val331) 
significantly lowered the production of cAMP without reducing receptor expression (196). In 
addition, deletion studies of GLP-1R suggest that a conserved Lys-Leu-Lys motif in the N-
terminal part of ICL3 plays a critical role for Gs-protein coupling (197), which is further 
supported by studies of synthetic peptide sequences derived from ICL3 of GLP-1R (198). 
Conversely, the C-terminal part of ICL3 may be involved in coupling to the Giα- subunit (198).  
The truncation experiments described in Study III indicate that the distal part of the GLP-1R C-
terminal tail is not involved in the signal transduction process. Similar observations have been 
made for other family B GPCRs (199;200). Instead, phosphorylation of three serine doublets in 
the distal part of the GLP-1R C-terminal (Ser441/Ser442, Ser444/Ser445 and Ser451/Ser452, Figure 
10) appears to be important for desensitisation and internalisation of the receptor (201).   
Small molecule ligands 
GLP-1 analogues have established a new class of drugs for the treatment of T2D, but have the 
disadvantage of not being orally available. Thus, small molecule agonists that target GLP-1R 
are preferable, but difficult to identify and develop, probably due to the large and open binding 
pocket of family B GPCRs. However, in recent years, several small molecule ligands have been 
discovered for GLP-1R. Most of these are merely used as research tools, but some may 
represent pharmacophores that can be optimised further for clinical development (202).  
 
Small molecule antagonists 
T-0632 was originally identified as an antagonist for the cholecystokinin (CCK) receptor (203), 
but was later shown to act as a non-competitive antagonist for GLP-1R (204). T-0632 binds to 
the human GLP-1R with an IC50-value of 1.2 µM, and was the first reported small molecule 
antagonist of GLP-1R. The authors identified a single residue, Trp33, in the ECD of GLP-1R that 
was involved in T-0632 binding, but not in GLP-1 binding (204). Trp33 does not make direct 
contact with GLP-1 when bound to ECD. The residue is positioned approximately 8 Å from the 
peptide binding pocket (162;175), which could explain the non-competitive, yet antagonistic 
properties of T-0632. A similar observation was made for the competitive antagonist 
olcegepant, which binds to the calcitonin gene-related peptide (CGRP) receptor (CGRP-R) ECD 
and blocks access to the peptide binding pocket (205). Other small molecule antagonists have 
been shown to target the TM domain of family B receptors. Site-directed mutagenesis of 
several residues in the TM domain of the rat GCGR identified residues in TM2 and TM3, whose 
substitution with Ala decreased the binding affinity of a small molecule GCGR antagonist, while 
preserving glucagon binding (206). Moreover, residues in the extracellular end of TM3 and TM5 
were shown to determine receptor-subtype selectivity of a small molecule antagonist of the 
CRFR1 receptor (207).  
A few small molecule antagonists have been identified that target GCGR as well as GLP-1R, 
suggesting that the two receptors may share a similar non-peptide binding pocket (208-210). 
In addition, the naturally occurring flavonoid, catechin, was recently found to act as a non-
competitive antagonist of GLP-1R (211).  
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Small molecule agonists 
A number of small molecules have been identified that activate GLP-1R (194;211-214) (Figure 
11). A screening of ~250.000 compounds identified a small molecule that stimulated cAMP 
production in transfected BHK cells expressing GLP-1R (213). Subsequent optimisation 
generated a full agonist, Compound 2 (Figure 11A) that stimulated cAMP production with an 
EC50 value of 0.10 µM (213). Compound 2 was also found to potentiate insulin secretion from 
isolated mouse pancreatic islets in a glucose dependent manner, whereas neither GLP-1 nor 
Compound 2 potentiated insulin secretion from islets of GLP-1R knockout mice (213). Other 
small molecule agonists like Boc5 (Figure 11B) and BETP (Figure 11C), have been identified 
that mimic the effects of GLP-1 in vitro and in vivo (212;214). The EC50 values of Boc5 and 
BETP were found to be 2.73 µM and 0.66 µM, respectively (212;214). A three-dimensional 
model structure of GLP-1R was used to predict the putative binding site of Boc5 to be located 
near the extracellular end of TM3 and TM4 (215). However, it is worth noting that the agonistic 
effect of Boc5, but not the agonistic effect of Compound 2 or BETP, was blocked by the GLP-1R 
antagonist exendin-4(9-39) (212-214). Hence, it appears that Boc5 binds to- or near the 
orthosteric binding site, whereas Compound 2 and BETP may bind to an allosteric site in GLP-
1R. A series of allosteric modulators of GLP-1R was reported recently based on naturally 
occurring as well as synthetic flavonoids (194;211). It has previously been reported that 
quercetin (Figure 11D), a naturally occurring flavonoid, has antidiabetic effects in rodents 
(216). Sexton et al. extended this work and showed that quercetin and quercetin-like 
compounds can modulate GLP-1R action in a ligand– and pathway dependent manner 
(194;211).  
Unfortunately, most the small molecule GLP-1R agonists developed to date are unsuitable for 
oral administration. Compound 2 and BETP are chemically unstable in the presence of 
nucleophiles, and the physiochemical properties of Boc5 render this compound incompatible 
with oral administration (202). However, Transtech Pharma has developed a series of potent 
small molecule GLP-1R agonists of which the leading compound, TTP054, is currently under 




Figure 11. Structures of small molecule ligands that target GLP-1R. Chemical structures of small molecule GLP-
1R ligands, based on four different scaffolds. (A) Compound 2 (213), (B) Boc5 (212), (C) BETP (214) and (D) 
Quercetin (194). 
 
Allosteric properties of small molecule ligands 
According to the classical definition, a positive allosteric modulator is a compound that binds to 
an allosteric site of a receptor, and enhances the effect of the endogenous agonist, without 
having any agonist activity itself (217). However, several compounds that act as agonists as 
well as allosteric modulators have now been identified (213;214;218;219) and termed ago-
allosteric modulators (220). Compound 2 and BETP are good examples of  
ago-allosteric modulators of GLP-1R. Both compounds stimulate cAMP production in cells 
expressing GLP-1R and both compounds increase glucose-dependent insulin secretion from 
isolated islets (213;214). The allosteric nature of the two small molecule agonists is supported 
by the observation that Compound 2 significantly increases the affinity of GLP-1 for GLP-1R 
(213), whereas BETP significantly increases the efficacy of GLP-1 (214) compared to GLP-1 
alone. In addition, BETP and Compound 2 appear to increase oxyntomodulin affinity for GLP-1R 
and oxyntomodulin-mediated activation of GLP-1R in a pathway-specific manner (194;221). 
Hence, BETP and Compound 2 increase oxyntomodulin-mediated signalling through the cAMP 
pathway, but not through other signalling pathways (194;221). Emerging evidence indicate 
that functional selectivity may be a relatively common feature of allosteric modulators of GLP-
1R. The naturally occurring, small molecule GLP-1R ligands quercetin and catechin were 
recently demonstrated to display functional selectivity. Quercetin potentiates the release of 
Ca2+ in a peptide-agonist dependent manner. That is, quercetin is unable to activate GLP-1R in 
the absence of a peptide agonist, but potentiates the release of Ca2+ induced by high affinity 
agonists like GLP-1 and exendin-4, but not by oxyntomodulin. Quercetin has no effect on 
peptide-induced signalling through other pathways (194). Conversely, catechin decreases GLP-
1 efficacy in the cAMP signalling pathway, but has no significant effect on other peptide 
agonists or other pathways (211).    
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Ago-allosteric modulators represent a new subclass of allosteric ligands, but more studies are 
required to fully understand the pharmacological potential of these dual-acting small 
molecules. The ago-allosteric nature and complex signalling profile of these ligands does 
however serve as an excellent tool to study GPCR pharmacology. It is now widely accepted 
that GPCR ligands can stabilise distinct receptor conformations and in this way elicit different 
signal transduction pathways (222). Hence, Compound 2 and BETP may stabilise a receptor 
conformation that favours binding of oxyntomodulin, which in turn favours signalling through 
the cAMP pathway. It has previously been suggested that ago-allosteric modulators could act 
in dimeric receptor setting (220), but this was recently disproved for GLP-1R (223). It was 
shown that GLP-1R forms homodimers via a TM4/TM4 interface similar to other family B GPCRs 
(224;225). Disruption of the dimer reduced peptide- and small molecule agonist potency in 
various signalling pathways, but the allosteric effects of Compound 2 and BETP were 
maintained, indicating that allosteric modulation of GLP-1R occurs in a single receptor setting 
(223).
 27 
RESULTS AND DISCUSSION 
The scientific work included in this thesis is dedicated to studying interactions between GLP-1R 
and receptor agonists. This section contains four studies (Study I-IV). The work included in 
Study I and II was published in 2010 and 2011, respectively, and Study III will be submitted 
to ‘Peptides’ in the near future. The two papers and the manuscript are included in the thesis 
immediately after a short introduction to each of the studies. Study IV contains unpublished 
data, but some of the results are included in a co-authored paper that is currently in 
preparation (226). 
Study I – Crystal structure of GLP-1-bound ECD of GLP-1R 
A part of the thesis work focused on identifying specific interactions between GLP-1 and the 
ECD of GLP-1R, as well as investigating the differential affinity of GLP-1 and exendin-4 for the 
ECD. The work resulted in a crystal structure of GLP-1 in complex with the ECD of GLP-1R 
(Figure 12A), which was published in Journal of Biological Chemistry in 2010. Throughout this 




Figure 12. Structure of GLP-1-bound ECD of GLP-1R. (A) GLP-1 (blue) bound to the ECD of GLP-1R (α-helix in 
black, β-strands in red, loops in grey and surface in white). Disulphide bonds are shown as orange sticks. GLP-1 is a 
continuous α-helix from Thr13* to Val33* with a kink around Gly22*. Thr13* and Val33* are shown as sticks. (B) GLP-1 
(blue, PDB IB: 3IOL) versus exendin-4(9-39) (orange, PDB ID: 3C59)-bound structure of the ECD (surface in white). 




In 2008, Runge et al. solved the crystal structure of GLP-1R ECD in complex with exendin-4(9-
39) (162), which for the first time elucidated ligand binding to GLP-1R on a detailed molecular 
level. The crystal structure solved during the Ph.D. work showed that GLP-1 is a continuous α-
helix from Thr13* to Val33* when bound to the ECD, but the helix has a distortion of the 
backbone around Gly22* (Figure 12). This distortion is not observed in the exendin-4(9-39)-
bound structure (Figure 12B). However, it is unclear whether a kinked helix is important for 
GLP-1 binding to GLP-1R or whether the kinked helix is a result of crystal packing. Site-
directed mutagenesis of the full-length GLP-1R subsequently demonstrated a ligand-specific 
effect of the Leu32-Ala mutation. Leu32 in the ECD of GLP-1R is positioned right next to the 
helix kink of GLP-1 (Figure 12B). This may be coincidental, but structural difference between 
GLP-1 and exendin-4(9-39) (kinked versus straight helix) could also explain the differential 
effect of the Leu32-Ala mutation on ligand binding. 
Study I was performed with help from Steffen Reedtz-Runge, who undertook the data 
collection and the structural determination of the complex. I did all the experimental work and 
wrote the manuscript. 
GLP-1 versus exendin-4  
Exendin-4 is a 39 amino acid peptide originally isolated from the venom of the lizard 
Heloderma suspectum, also known as the Gila monster (65). GLP-1 and exendin-4 are 
approximately 50% identical (Figure 13C).  
 
 
Figure 13. GLP-1 versus exendin-4. (A) Solution NMR structure ensemble of GLP-1 in 35% trifluoroethanol (TFE) 
(PDB ID: 1D0R, (227)). (B) Solution NMR structure ensemble of exendin-4 in 30% TFE (PDB ID: 1JRJ, (228)). The α-
helices and loops are shown in red and green, respectively. Residues shown as sticks: Phe28*, Ile29*, Trp31* and Leu32* 
of GLP-1 and Val19**, Phe22**, Ile23**, Trp25** and Leu26** of exendin-4. Leu21**-Pro38** of exendin-4 form a tertiary 
structure known as the Trp-cage, which shields the side chain of Trp25** from solvent exposure (228). (C) Sequence 
alignment of GLP-1 and exendin-4, with conserved residues highlighted in grey. The highest degree of identity is found 
in the N-terminal part of the peptides, where 9 out of 11 residues are conserved. Residue number 1 of exendin-4 
corresponds to residue number 7 of GLP-1. 
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As mentioned, GLP-1, exendin-4 and the N-terminally truncated exendin-4(9-39) bind to the 
full-length GLP-1R with almost similar affinity (IC50 ~0.5 nM). However, GLP-1 binds to the 
isolated ECD with reduced affinity (IC50 > 500 nM), whereas exendin-4 and exendin-4(9-39) 
maintain high affinity for the isolated ECD (IC50 = 6 nM) (173;174). This discrepancy in binding 
modes was initially explained by an additional interaction between the Trp-cage motif of 
exendin-4 and the ECD of GLP-1R (229). In TFE, the C-terminal extension of exendin-4 folds 
back onto the central part of the peptide and forms a protein-like fold known as the Trp-cage 
(Figure 13B) (228), which is not observed in GLP-1 (Figure 13A). In fact, the helical portion of 
GLP-1 is less stable than that of exendin-4 in TFE (228), and GLP-1 is almost devoid of 
secondary structure in aqueous buffer (230). It was later shown that the differential affinity for 
the GLP-1R ECD can be explained almost entirely by divergent residues in the central helical 
parts of GLP-1 and exendin-4 (174). These divergent residues (Glu21*-Arg36* in GLP-1 and 
Glu15**-Gly30** in exendin-4) render exendin-4 more helical in solution compared to GLP-1 
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GLP-1 (glucagon-like peptide-1) is an incretin released from
intestinal L-cells in response to food intake. Activation of the
GLP-1 receptor potentiates the synthesis and release of insulin
from pancreatic -cells in a glucose-dependent manner. The
GLP-1 receptor belongs to class B of theG-protein-coupled recep-
tors, a subfamily characterized by a large N-terminal extracellular
ligand binding domain. Exendin-4 and GLP-1 are 50% identical,
and exendin-4 is a full agonist with similar affinity and potency for
theGLP-1 receptor.We recently solved the crystal structure of the
GLP-1 receptor extracellular domain in complexwith the compet-
itive antagonist exendin-4(9–39). Interestingly, the isolated extra-
cellulardomainbindsexendin-4withmuchhigheraffinity thanthe
endogenous agonistGLP-1.Here, we have solved the crystal struc-
ture of the extracellular domain in complex with GLP-1 to 2.1 A˚
resolution. The structure shows that important hydrophobic
ligand-receptor interactions are conserved in agonist- and antago-
nist-bound forms of the extracellular domain, but certain residues
in the ligand-binding site adopt a GLP-1-specific conformation.
GLP-1 isakinkedbutcontinuous-helix fromThr13 toVal33when
bound to the extracellular domain. We supplemented the crystal
structure with site-directed mutagenesis to link the structural
information of the isolated extracellular domain with the bind-
ing properties of the full-length receptor. The data support the
existence of differences in the binding modes of GLP-1 and
exendin-4 on the full-length GLP-1 receptor.
GLP-1 (glucagon-like peptide-1) is a peptide hormone pro-
duced by post-translational processing of proglucagon in the
intestinal L-cells (1). GLP-1 is an incretin that potentiates the
synthesis and release of insulin from pancreatic -cells in a
glucose-dependent manner (2) and has a number of other ben-
eficial effects that contribute to reducing blood sugar (3–6). In
addition, GLP-1 has been shown to reduce bodyweight (3, 5, 7),
which is favorable formany people with type 2 diabetes. Hence,
GLP-1-based therapies are becoming increasingly attractive for
the treatment of type 2 diabetes. The actions of GLP-1 are
mediated through the GLP-1 receptor (GLP-1R),3 which is a
seven-transmembrane G protein-coupled receptor (GPCR)
coupled to adenylyl cyclase (8). The human GLP-1R was first
cloned in 1992 and belongs to class B of GPCRs (9). This class
includes a wide range of receptors for peptide hormones like
glucagon, GLP-2 (glucagon-like peptide-2), glucose-
dependent insulinotropic polypeptide (GIP), pituitary aden-
ylyl cyclase-activating polypeptide (PACAP), vasoactive
intestinal polypeptide, secretin, calcitonin, corticotrophin-
releasing factor, and parathyroid hormone (PTH) (10). The
receptors are distinguished by their large extracellular
N-terminal domain (ECD), which is important for ligand
binding and selectivity (11, 12). The current binding model
suggests a two-domain mechanism where the C-terminal
part of the ligand binds the ECD and the N-terminal part of
the ligand binds the extracellular loops and transmembrane
-helices (TM domain), which leads to receptor activation
(reviewed in Ref. 13).
The first structure of an isolated ECD of a class B GPCR
was solved recently by NMR spectroscopy (14). Subse-
quently, structures of ligand-bound ECDswere solved, includ-
ing the ECD of the human type 1 corticotrophin-releasing fac-
tor receptor 1 (15), the human type 1 PACAP receptor (16), the
human GIP receptor (17), the human GLP-1R (18), and the
human type 1 PTH receptor (19). The ECDs of class B receptors
have a common structure, the secretin recognition fold, which
is stabilized by three conserved disulfide bonds and five con-
served residues (Asp67, Trp72, Pro86, Gly108, andTrp110 inGLP-
1R). The receptor-bound ligands are primarily in-helical con-
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formation, and the C-terminal part of the ligands binds the
ECD in agreement with the two-domain binding mechanism.
Several receptor models have been proposed for full-length
class B receptors (20–23). However, the orientation of the ECD
relative to the TM domain is uncertain.
Exendin-4 is a 39-amino acid peptide, which was originally
isolated from the venom of the lizard Heloderma suspectum
(24). GLP-1 and exendin-4 are 50% identical, and exendin-4 is a
full agonist with similar affinity and potency for the full-length
GLP-1R (25). However, structure-activity studies have demon-
strated interesting differences between the binding modes of
GLP-1 and exendin-4. 1) The isolated ECD binds exendin-4
with high affinity (IC50 of 6 nM) and GLP-1 with low affinity
(IC50500 nM) (26, 27). 2) GLP-1 binding is more sensitive to
site-directed mutagenesis of the TM domain compared with
exendin-4 binding (28–30). 3) GLP-1 ismuchmore sensitive to
N-terminal truncation than exendin-4 (31). N-terminally trun-
cated exendin-4 variants maintain high affinity but are unable
to activate GLP-1R, i.e. competitive antagonist, whereas N-ter-
minal truncation of GLP-1 severely affects both binding and
activation (31). Clearly, the interaction between theN-terminal
part of GLP-1 and the TM domain is critical for binding and
activation of GLP-1R.
Exendin-4(9–39) is a truncated form of exendin-4, and a
competitive antagonist that maintains high affinity for GLP-1R
through interactions with the ECD (IC50 value of 6 nM for the
isolated ECD) (27, 32). We recently solved the crystal structure
of the GLP-1R ECD in complex with exendin-4(9–39) (18).
Exendin-4(9–39) is -helical in the ECD-bound conformation
except for the C-terminal segment, the so-called Trp cage (33,
34). In solution, the helical propensity of exendin-4 is higher
than that of GLP-1 (27, 33). Biophysical studies showed a pos-
itive correlation between -helical propensity in solution and
affinity for the GLP-1R ECD (27). Moreover, charged residues
of exendin-4 interact with the ECD in amanner not possible for
GLP-1 (18). Hence, the high affinity of exendin-4 for the ECD
may be a combination of high helical propensity in solution and
unique receptor interactions.
Here, we report the crystal structure of the GLP-1R ECD in
complex with its endogenous agonist GLP-1. We supple-
mented the crystal structure with site-directed mutagenesis to
link the structural information of the isolated ECD with the
binding properties of the full-length receptor.
EXPERIMENTAL PROCEDURES
Protein and Peptide Preparation—The GLP-1R ECD was
prepared as described previously (27). Briefly, N-terminal His6-
tagged ECD was expressed in Escherichia coli inclusion bodies,
isolated as inclusion body protein, solubilized in guanidine-HCl
and dithiothreitol, dialyzed against guanidine-HCl to remove
the dithiothreitol, and refolded using L-Arg and a 1:5 molar
ratio of reduced and oxidized glutathione. The refolded ECD
was purified by hydrophobic interaction chromatography and
size exclusion chromatography in 10 mM Tris-HCl, pH 7.5, 0.1
M Na2SO4, 2% glycerol. The His6 tag was removed by thrombin
cleavage. The purified GLP-1R ECD consisted of four amino
acids, Gly-Ser-His-Met, of the linker attached to the N-termi-
nus of ECD (Arg24–Tyr145),Mr 14,723 g/mol after removal of
the His6 tag. Native GLP-1(7–37)-OH was synthesized as
described previously (12).
Purification and Crystallization of the GLP-1-bound Extra-
cellularDomain—The purifiedGLP-1R ECDwas concentrated
to 1.2 mg/ml, mixed with 3-fold molar excess of GLP-1(7–37)
(dissolved in 50mMTris-HCl, pH 7.5), and incubated overnight
at 4 °C. The GLP-1-bound ECD was purified by size exclusion
chromatography on a Superdex 75 column in 10 mM Tris-HCl,
pH 7.5, at a flow rate of 0.3 ml/min and characterized by SDS-
PAGE (supplemental Fig. S1). The complex was concentrated
to 4 mg/ml and crystallized by hanging drop vapor diffusion.
The crystallization conditions were initially identified using the
Crystal Screen fromHampton Research and subsequently opti-
mized to 0.1 M N(2-acetamido)iminodiacetic acid, pH 6.9, 14
volume % ()-2-methyl-2,4-pentanediol and 9 mM n-decyl--
D-thiomaltoside. Single crystalswere flashed cooled in liquidN2
using 30% glycerol in the cryo solution.
Data Collection and Structure Determination—Diffraction
data were collected from a single crystal using beamline 1911-3
at MAX-lab (Lund, Sweden). The data were integrated and
scaled using XDS (35). The crystals belonged to space group
P21221with the unit cell dimensions a 35.7Å, b 42.7Å, and
c 95.1 Å. The phases and electron densitymapwere obtained
by molecular replacement using Phaser running in the CCP4
program interface with one complex in the asymmetric unit.
Refinement was done using COOT (36) and REFMAC5 (37).
Well defined electron density was obtained for GLP-1 residues
Thr11*–Val33* and for ECD residues Val30–Glu128. Poor den-
sity was observed for GLP-1 residues Gly10*, Lys34*, and Gly35*
and ECD residues Thr29 and Asn115. No electron density was
observed for His7*–Glu9* and Arg36*–Gly37* of GLP-1. Our
final structure containsGLP-1 residuesGly10*–Gly35* and ECD
residues Thr29–Glu128, but it should be noted that the confor-
mation of Lys34* of GLP-1 is very uncertain, and because of the
poor density we have chosen to show Asn115 as Gly. The final
GLP-1-bound ECD structure has 116 residues in preferred
regions, 5 in allowed regions and only 1 outlier (Glu68 in the
-turn between 1 and 2 shown in Fig. 1A) in the Ramachan-
dran plot. The structure containing 73 water molecules and a
detergent molecule (n-decyl--D-thiomaltoside) has a working
R-factor of 0.181% and a freeR-factor of 0.226%.Data collection
and refinement statistics are summarized in Table 1. Coordi-
nates and structure factors are deposited in the Protein Data
Bank under accession code 3IOL.Molecular graphics were pre-
pared in PyMOL (46).
Receptor Constructs—The cDNA encoding the human GLP-
1R was originally obtained from Dr. B. Thorens (9) and sub-
cloned into the mammalian expression vector pcDNA3.1/
v5-His-TOPO (Invitrogen). The presence of the C-terminal
His6 tag was previously shown not to influence the functional
response of the receptor (12). Site-directed mutagenesis of
GLP-1R was done using QuikChangeTM (Stratagene). Plasmid
DNAwas generated using the NucleoBondXtraMaxi Plus kit
(Macherey-Nagel), and the desired mutations were confirmed
by dideoxynucleotide sequencing.
Cell Culture and Receptor Expression—Human embryonic
kidney (HEK) 293 cellsweremaintained inDulbecco’smodified
Eagle’s medium (BioWhittaker) supplemented with 10 volume
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% fetal bovine serum and 1 volume % penicillin/streptomycin
(100 units/ml) in T175 flasks. HEK293 cells were transiently
transfected with 21 g of GLP-1R DNA using the FuGENETM
transfection reagent (Roche Applied Science), harvested
24 h after transfection, and used directly in functional exper-
iments or plasma membrane preparations as described pre-
viously (12).
Functional Assay—Transiently transfected HEK293 cells
expressing wild-type GLP-1R or mutant receptors were har-
vested and resuspended in assay buffer (Flashplate,
PerkinElmer Life Sciences) to a cell density of 2.4  106 cells/
ml. GLP-1(7–37)-acid and exendin-4 were diluted in phos-
phate-buffered saline with 0.02 volume % Tween 20. Cells in
assay buffer (50l) and GLP-1 or exendin-4 (50l) weremixed
in 96-well FlashPlates (PerkinElmer Life Sciences), gently agi-
tated for 5min, and incubated for 25min at room temperature.
The resulting intracellular level of cAMPwasmeasured accord-
ing to supplier’s manual and analyzed by nonlinear regression/
sigmoidal dose-response fitting using Prism 5.0 (GraphPad
Software, Inc.).
Receptor Binding Assay—Freshly
thawed plasma membrane prepara-
tions from transiently transfected
HEK293 cells expressing GLP-1R
(20 g protein/well) were pulled
through a 25-gauge needle three
times and diluted in assay buffer (50
mM HEPES, 5 mM MgCl2, 5 mM
EGTA, 0.005 volume % Tween 20,
pH 7.4). GLP-1 and exendin-4 were
diluted in assay buffer. The concen-
tration range was 1 pM to 100 nM
for GLP-1 and exendin-4. 125I-GLP-
1(7–36)-amide (2.2 Ci/mol) was
dissolved in assay buffer and added
at 50,000 cpm per well to a final
concentration of 50 pM. Nonspe-
cific binding was determined with
1 M GLP-1. Membrane prepara-
tion and radioligand were mixed in
96-well 0.65-m filter plates (Milli-
pore) with either diluted GLP-1 or
exendin-4 and incubated for 1 h at
37 °C. Subsequently, bound and
unbound radioligands were sepa-
rated by vacuum filtration (Milli-
pore vacuum manifold). The filters
were washed twice in 100 l of cold
assay buffer and left to dry. Data
were analyzed by nonlinear regres-
sion, and the expression level (Bmax)





1R ECD was expressed in E. coli
inclusion bodies, refolded, and purified as described previously
(27). A complex of GLP-1 and the ECD was purified by size
exclusion chromatography (supplemental Fig. S1). The purified
complex was characterized by SDS-PAGE (supplemental Fig.
S1), concentrated, and crystallized by hanging drop vapor dif-
fusion. Diffraction data were collected from a single crystal
using the beamline 1911-3 at MAX-lab (Lund, Sweden), and
the structure of GLP-1 in complex with the GLP-1R ECDwas
solved to 2.1 Å resolution by molecular replacement (Fig.
1A). We removed exendin-4(9–39) from the structure of the
exendin-4(9–39)-ECD complex (Protein Data Bank code
3C59) and used the apo-form of GLP-1R ECD as the search
model for the molecular replacement. GLP-1 was then built
into themodel; its position was unambiguous due to good elec-
tron density for most of the ligand. Data collection and refine-
ment statistics are summarized inTable 1. Throughout the text,
GLP-1 and exendin-4 residues are designated with * and **,
respectively. Exendin-4 is numbered 1–39 and GLP-1 is num-
bered 7–37, due to post-translational processing. The aligned
sequences are illustrated in Fig. 1B.
FIGURE 1. Structure of the GLP-1-bound ECD of the GLP-1R. A, stereoview of GLP-1 (blue) bound to the ECD
of theGLP-1R (-helix in black,-strands in red, and loops in gray). Disulfide bridges are shown as orange sticks.
Residues Cys62–Asp67 (1) and Ala
70–Gly75 (2) constitute the first region of antiparallel -sheets, and the
second region is comprised of residues Gly78–Ser84 (3) and His
99–Thr105 (4), which is shown in red. Our final
structure contains GLP-1 residues Gly10*–Gly35*. The residues that interact with GLP-1R ECD lie within Ala24*
and Val33*, which are shown as sticks. B, sequence alignment of GLP-1, exendin-4, GIP, GLP-2, glucagon, and
PACAP(1–27). Fully conserved residues are highlighted in yellow, and partially conserved residues are high-
lighted in green. The residues of GLP-1 and exendin-4 that interact with GLP-1R ECD are colored blue. The
underlined residues symbolize residues of GLP-1 in -helical conformation when bound to the ECD. Residue
number 1 of exendin-4 corresponds to residue number 7 of GLP-1.
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Structure of the GLP-1R Extracellular Domain—The crystal
structure of the ECD in the GLP-1-bound form shown here is
very similar to the exendin-4(9–39)-bound form shown previ-
ously (root mean square deviation of 0.79 Å for C atoms of the
ECD) (18). The ligand-binding sites are identical, which is not
surprising given the competitive binding of GLP-1 and
exendin-4 for the full-length GLP-1R as well as the isolated
ECD (27). However, we have previously shown that divergent
residues in the two ligands are responsible for their different
physical properties in solution and their different affinity for
the ECD (27). As described below, these divergent residues give
rise to structural differences in the two ligand-bound forms of
the ECD at the level of specific side chain conformations.
Structure of GLP-1 and Its Interactions with the Extracellular
Domain of GLP-1R—GLP-1 is a continuous -helix from
Thr13* to Val33*, with a kink around Gly22*. The residues
between Ala24* and Val33* interact with the ECD (Fig. 1, A and
B). The amphiphilic nature of this -helical segment enables
hydrophilic and hydrophobic interactions through opposite
faces of the -helix. The hydrophilic face is comprised by resi-
dues Gln23*, Lys26*, Glu27*, and Lys34*. Lys26* is the only one of
these thatmay interact directlywith the ECD (Fig. 2A). The side
chain of Lys26*may formahydrogen bondwith the side chain of
Glu128 (3.0Å), but theB-factor is rather high for both residues
(25 compared with 10 for well defined residues), suggesting
that this is not a strong interaction. In particular, the electron
density of the Lys26* side chain is rather weak. In exendin-4(9–
39), the amphiphilic character is more pronounced, and the
-helical conformation is further stabilized by intramolecular
interactions between Glu16**, Glu17**, Arg20**, Glu24**, and
Lys27** on the hydrophilic face (18). In addition, Arg20** and
Lys27** interact withGlu128 andGlu127 of the ECD, respectively
(18). The corresponding intramolecular stabilization is not pos-
sible in GLP-1 due to a less favorable alignment of oppositely
charged residues (Fig. 1B), and Glu127 of the ECD is not
involved in binding of GLP-1 (Fig. 2A).
The hydrophobic face of GLP-1, which interacts with the
ECD, is defined by Ala24*, Ala25*, Phe28*, Ile29*, Leu32*, and
Val33* (Fig. 2B). The importance of Phe28*, Ile29*, and Leu32* in
GLP-1 binding has been demonstrated previously by Ala scan-
ning of GLP-1 (38). Substitution of Phe28* with Ala had the
most severe effect on GLP-1 affinity in the Ala scan (IC50 value
increased by 1300-fold), and indeed Phe28* is centrally posi-
tioned in the ligand-receptor interface emphasizing the impor-
tance of this hydrophobic ligand-receptor interaction. The
I29*A and L32*A substitutions also reduced GLP-1 affinity sig-
nificantly (IC50 value increased by 93- and 17-fold, respectively)
(38). Trp31* is also on the hydrophobic face of GLP-1 but is
rather solvent-exposed and does not interact with the ECD
(Fig. 2B). Trp31* is conserved in the
glucagon peptide family (GLP-1,
exendin-4, glucagon, GIP, and
GLP-2, see Fig. 1B), which implies a
unique role of this residue. How-
ever, substitution of Trp31* with Ala
only reduced the binding affinity of
GLP-1 slightly at the full-length
GLP-1R (38), so the role of Trp31* in
receptor binding is unclear.
Val33* is the final residue in the
-helix of GLP-1, and it is the final
residue in the C terminus of GLP-1
that interacts with the ECD (Fig. 2,
A and C). The side chain of Val33*
makes hydrophobic contacts with
Tyr69 and Leu123, and the backbone
carbonyl of Val33* interacts through
a hydrogen bondwith one of the ter-
minal nitrogens of Arg121 (Fig. 2, A
andC). The other terminal nitrogen
ofArg121 interactswith awatermol-
FIGURE 2. Interactions between GLP-1 and GLP-1R ECD. A, ribbon diagram of GLP-1 and its hydrophilic
interactionswithGLP-1RECD.GLP-1 is colored in cyan, and residuesGln23*, Lys26*, Glu27*, Trp31*, andVal33* are
illustrated as sticks. Receptor residues Arg121, Leu123, Glu127, and Glu128 are shown as sticks. The surface of the
hydrophilic binding cavity of ECD is illustrated in gray. B, ribbon diagram of GLP-1 and its hydrophobic inter-
actions with GLP-1R ECD. GLP-1 residues Ala24*, Glu27*, Phe28*, Trp31*, and Leu32* are illustrated as sticks, and
so are ECD residues Leu32, Trp39, Asp67, and Arg121. The surface of the hydrophobic binding cavity of ECD is
illustrated in gray. C, ribbon diagram illustrating a common motif found in the GLP-1R ECD and in the GIP
receptor ECD. The side chain of Arg121 interacts with the backbone carbonyls of Asp67 and Leu32* through a
water molecule. GLP-1 residues Leu32* and Val33* are illustrated as sticks, and so are ECD residues Asp67 and
Arg121.
TABLE 1
Data collection and refinement statistics
The data set was collected from a single crystal. Values in parentheses are for the
highest resolution shell (2.2-2.1 Å).
Space group P21221













No. of non-hydrogen atoms 1109
Resolution 95.1-2.1 Å (2.155-2.100 Å)
Total reflections 8786




Root mean square deviation
Bond lengths 0.02 Å
Bond angles 1.7°
Crystal Structure of Receptor-bound GLP-1
726 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 285•NUMBER 1•JANUARY 1, 2010
ecule, which is also coordinated by the backbone carbonyl
groups of Asp67 and Leu32* (Fig. 2C). A water molecule is coor-
dinated by the same residues in the exendin-4(9–39)-bound
ECD, and Arg121 interacts with the backbone carbonyl of
Lys27** of exendin-4(9–39) in a manner similar to the interac-
tion with Val33* of GLP-1. Even though exendin-4 has a C-ter-
minal nine-residue extension, the so-calledTrp cage, the extent
of the -helix is similar for GLP-1 and exendin-4, and this par-
ticular length of the -helix fits nicely into the ECD binding
pocket.
Judging from the two ligand-bound ECD structures, the
hydrophobic ligand-receptor interface is highly conserved, and
the C-terminal -helical structure of the ligands ends at the
same position with a similar arrangement of receptor interac-
tions mediated by the backbone of the ligand. Hence, the dif-
ferential affinity for the ECDmay best be explained by the lower
-helical propensity of GLP-1 in solution and by weaker recep-
tor interactions compared with exendin-4, as suggested previ-
ously (27).
Unique Structural Features of the GLP-1-bound Extracellu-
lar Domain—The divergent residues in GLP-1 and exendin-4
are not only responsible for the different physical properties
of the ligands in solution and their differential affinity for the
GLP-1R ECD, they also influence the conformation of certain
residues in the ECD structures. The crystal structure presented
here suggests that one diverging residue in the two ligands
(Val33* of GLP-1 and Lys27** of exendin-4(9–39)) causes a shift
in the conformations of four residues in (or close to) the binding
pocket of the ECD, namely Glu127, Leu123, Arg121, and Pro119
(Fig. 3A). In exendin-4(9–39), Lys27** interacts with Glu127,
and the positioning of the Lys27** side chain appears to be
guided by a hydrophobic interaction with Leu123. In GLP-1,
Val33* is unable to interact with Glu127 causing Glu127 to
change rotamer conformation and point its side chain away
from GLP-1. The side chain of Leu123 is flipped toward Arg121,
which again is flipped toward
Pro119, thereby closing an otherwise
water-accessible cavity observed in
the exendin-4(9–39)-bound struc-
ture (Fig. 3A). The closing of this
cavity is assisted by a side chain flip
of Pro119 toward Arg121. The appar-
ent GLP-1-specific conformations
affect the conserved core of the ECD
by rotating the guanidine group of
Arg102 and by decreasing the dis-
tance between Asp67 and Arg102
compared with the exendin-4(9–
39)-bound structure without affect-
ing the relative position and confor-
mation of Trp72 and Trp110 (Fig.
3B). This enables a direct interac-
tion through a hydrogen bond
between Asp67 and Arg102 unlike
what we observed in the exendin-
4(9–39)-bound structure, where a
water molecule mediated the inter-
action between Asp67 and Arg102
(Fig. 3B). The functional consequences of the ligand-specific
conformational differences are not known.
Site-directed Mutagenesis of the GLP-1R—To link the struc-
tural information of the isolated ECD with the binding and
functional properties of the full-length receptor, we targeted
the ligand-binding site of the ECD by site-directed mutagene-
sis. The mutants were characterized by their ability to bind
GLP-1 and exendin-4, using the agonist 125I-GLP-1 tracer, and
by their ability to stimulate cAMP production in response to
GLP-1 and exendin-4 (Table 2). The main objective was to
search for mutations with differential effect on GLP-1 and
exendin-4. We initially focused on Glu127, which showed an
obvious conformational difference in the two ligand-bound
structures (Fig. 3A), Glu127 interacts directly with exendin-
4(9–39) but not with GLP-1 (18). The ECD structures suggest
that the hydrogen-bonding potential of Glu127 is important for
exendin-4 binding but not for binding of GLP-1, and this is
supported by the site-directed mutagenesis data (Table 2).
Mutation ofGlu127 toAla reduced the affinity for exendin-4 but
not for GLP-1 (6.8- versus 1.7-fold, respectively). Glu128 inter-
acts with a positively charged residue in both GLP-1 and
exendin-4, which may explain why the E128A substitution did
not have a differential effect on the binding affinity of GLP-1
and exendin-4. The differential effect of the E127Amutation on
GLP-1 and exendin-4 binding is rather small compared with
the differential affinity of the isolated ECD shown previously
(27). Clearly, the superior helical propensity of exendin-4 con-
tributes strongly to its high affinity for the ECD.
Several interactions are conserved in the twoECDstructures,
and mutagenesis of the implicated receptor residues was not
expected to have differential effects on ligand binding (Table 2).
Surprisingly, the L32A mutation reduced both the affinity
and potency of exendin-4 relative to GLP-1 (7.1- and 9.5-fold,
respectively, see Table 2 and Fig. 4), demonstrating a ligand-
specific effect of the L32A mutation. Neither the potency nor
FIGURE3.DifferencesbetweentheGLP-1-andexendin-4(9–39)-boundstructureofECD.Ribbondiagrams
showing significant differences in side chain conformations between the GLP-1-bound structure and the
exendin-4(9–39)-bound structure of GLP-1R ECD. Receptor and ligand residues are highlighted in blue for the
GLP-1-bound structure and in orange for the exendin-4(9–39)-bound structure.Watermolecules in orange are
present only in the exendin-4(9–39)-bound structure. A, one diverging residue, Val33* of GLP-1 and Lys27** of
exendin-4(9–39), causes a shift in the conformations of four residues, namelyGlu127, Leu123, Arg121, and Pro119.
B,GLP-1-specific conformations affect the conserved coreof the ECDby rotating theguanidinegroupofArg102
and by decreasing the distance between Asp67 and Arg102 compared with the exendin-4(9–39)-bound struc-
ture without affecting the relative position of Trp72 and Trp110.
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the affinity ofGLP-1was affected by the L32Amutation (Fig. 4),
and the expression level of the receptorwas similar towild-type
GLP-1R, which confirmed the structural integrity of this
receptor mutant. Leu32 is the first
residue in the-helix of theGLP-1R
ECD, and it defines the border of
the hydrophobic binding cavity by
interacting with Ala24*, Ala25*, and
Phe28* (Fig. 2B). The results suggest
that Leu32 is important for the bind-
ing of exendin-4 but not for the
binding of GLP-1 to GLP-1R. It is
difficult to give a structural explana-
tion of the ligand-specific effect of
the L32A mutation by comparing
the two ligand-bound forms of the
ECD, because the structural differ-
ences in this region are quite subtle.
Nevertheless, the ligand-specific
effect of the L32A mutation sup-
ports the existence of differences in
the binding modes of GLP-1 and
exendin-4 to the full-length GLP-1R.
Clearly, the two-domain binding
mechanism of the full-length GLP-
1R is more complex than binding of
the isolated ECD.
Conformation of GLP-1, Recep-
tor-bound and in Solution—GLP-1
is highly flexible in aqueous buffers,
whereas in trifluoroethanol a single-
stranded -helix forms (Thr13* to
Lys34*) with a less defined -helical
region around Gly22*, as demon-
strated by NMR spectroscopy (33,
39). Structure-activity studies of
GLP-1 showed that side chain to
side chain cyclization by lactam
bridge formation of residues 16–20
and 18–22 were well tolerated. Cyclization of residues 11–15
improved potency for GLP-1R compared with the linear coun-
FIGURE4.Functional andbindingproperties of the L32AGLP-1Rmutant.Upper panel, stimulationof cAMP
production by transiently transfected HEK293 cells expressing the L32A mutant by GLP-1 (squares, A) and
exendin-4 (circles, B).Dashed dose-response curves represent cAMPproduction by GLP-1 and exendin-4 at the
wild-type GLP-1R, respectively. Lower panel, competition binding assay on plasma membranes from tran-
siently transfectedHEK293 cells expressing the L32Amutant. GLP-1 binding curves are presentedwith squares
(C) and exendin-4 curves with circles (D). Dashed binding curves represent 125I-GLP-1 displacement by GLP-1
andexendin-4 at thewild-typeGLP-1R.Data arenormalizedaccording to 125I-GLP-1bindingandcorrespond to
three independent experiments performed in duplicate.
TABLE 2
Functional and binding experiments with GLP-1Rmutants
EC50 and IC50 values are given in pM and nM, respectively, and expression levels are given in fmol/mg total protein. Data represent the mean  S.E. of three or more
independent experiments performed in duplicate. The EC50 or IC50 values of GLP-1 and exendin-4 are compared with the wild-type GLP-1R using the unpaired t test.
Numbers in parentheses equal the relative difference between EC50 or IC50 values of GLP-1 and exendin-4 at eachmutant comparedwith the wild-type receptor. NDmeans
not detectable, possibly due to no expression or no binding. * indicates p 0.05; **, p 0.01; and no asterisk means no significant difference.
Mutant EC50 IC50 Expression levelGLP-1 Exendin-4 GLP-1 Exendin-4
pM nM fmol/mg
Wild type 11 3.2 5.5 1.7 1.0 0.20 0.76 0.19 5.5 0.16
L32A 12 2.7 (1.1) 52 24 (9.5) 1.1 0.17 (1.1) 5.4 1.5* (7.1) 6.0 0.40
T35A 30 7.4 (2.7) 23 12 (4.2) 3.1 0.80 (3.1) 0.44 0.1** (0.6) 0.38 0.01
V36A 57 32 (5.2) 36 20 (6.5) 2.8 0.86 (2.8) 0.98 0.34 (1.3) 5.7 0.28
E68A 15 2.4 (1.4) 9.5 4.2 (1.7) 1.9 0.90 (1.9) 0.48 0.07 (0.6) 5.7 0.07
Y69A ND ND ND ND ND
Y88A ND ND ND ND ND
L89A ND ND ND ND ND
P90A 55 12* (5.0) 30 7.3* (5.5) 2.8 1.6 (2.8) 1.6 0.28 (2.1) 5.6 0.22
R121A 51 13* (4.6) 44 10* (8.0) 2.3 1.1 (2.3) 1.2 0.02 (1.6) 5.7 0.37
L123A 17 4.6 (1.5) 9.5 1.9 (1.7) 1.1 0.38 (1.1) 0.33 0.04 (0.4) 2.6 0.09
E127A 13 4.2 (1.2) 11 0.45* (2.0) 1.7 0.76 (1.7) 5.2 2.0 (6.8) 5.6 0.46
E127Q 12 3.3 (1.1) 6.8 1.4 (1.2) 1.1 0.27 (1.1) 0.82 0.15 (1.1) 6.11 0.21
E128A 28 6.2 (2.5) 25 6.7* (4.5) 2.7 0.91 (2.7) 1.8 0.48 (2.4) 6.0 0.49
E128Q 10 3.0 (0.9) 8.0 3.3 (1.5) 0.66 0.11 (0.7) 0.45 0.1 (0.6) 5.2 0.12
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terpart (40, 41). These data support the existence of an-helical
conformation in the N-terminal part of GLP-1 when bound to
the full-length GLP-1R. It is interesting that in the ECD-bound
structure, the Thr13*–Glu21* segment of GLP-1 adopts an
-helical conformation even though this segment does not
interact with the ECD. The C-terminal segment of GLP-1
(Ala24*–Val33*) is stabilized in a specific-helical conformation
throughbinding to the ECD.Thismay subsequently stabilize an
-helical conformation in the N-terminal part of the ligand
(Thr13*–Glu21*). This hypothesis is supported by the solution
structure of GLP-1 in different concentrations of trifluoroetha-
nol (39). GLP-1 is a random coil in pure water, but adding tri-
fluoroethanol enables the C-terminal segment of GLP-1 to
adopt an-helix conformation. TheC-terminal-helix is grad-
ually extended toward the N-terminus of the peptide with
increasing concentrations of trifluoroethanol (39), and it seems
possible that a similar mechanism is initiated upon binding of
GLP-1 to the ECD. It was recently proposed that -helix for-
mation of the ligand upon binding
to the ECD is an important step in
the activation of class BGPCRs (23).
As shown in Fig. 5A, the -helix
of GLP-1 has a central distortion of
the backbone around Gly22*, which
is not observed in the exendin-4(9–
39)-bound structure. The distortion
is also observed in the NMR struc-
tures of GLP-1 in solution (39).
However, we cannot exclude that
the kink observed in the crystal
structure is a result of crystal pack-
ing between the N-terminal part of
GLP-1 (Gly10*–Glu21*) and symme-
try-related ECDs rather than a func-
tionally important characteristic of
GLP-1 (Fig. 5, B–D). Substitution of
Gly22*withAlawas previously shown
not to affect the functionality or the
binding affinity of GLP-1, which sug-
gests that flexibility around Gly22* is
not required for binding to or acti-
vation of GLP-1R (38). Interest-
ingly, Leu32 of the ECD is positioned
right next to the kink of GLP-1 (Fig.
5A). Thus, we have demonstrated a
ligand-specific effect of the L32A
mutation and have shown that
ECD-bound GLP-1 has a kink right
next to Leu32, whereas ECD-bound
exendin-4(9–39) is straight. This
may be a coincidence, but it is
tempting to speculate that there is a
connection between the structural
difference of the ligands (kinked or
straight helix) and the differential
effect of the L32A mutant on bind-
ing of the ligands.
A three-dimensional model of
GLP-1R was recently published (21). From the NMR structure
of GLP-1 in trifluoroethanol (Protein Data Bank code 1D0R
(39)), it was suggested that GLP-1 might assume one of two
forms when bound to GLP-1R, a slightly kinked -helix or an
L-shaped -helix, and the authors concluded that the L-shaped
-helix conformation of GLP-1 seemed more reasonable
(21). The crystal structure presented here is more compatible
with the kinked conformation of GLP-1.
The structure of His7*–Gly10* was not determined in this
study probably due to the inherent flexibility in this part of
GLP-1 and other peptide ligands for class B receptors (33, 39,
42, 43). The only structural evidence showing a unique confor-
mation comes from a structural study of PACAP(1–21) com-
paring micelle- and receptor-bound states. Residues 1–7 of
PACAP(1–21) adopt a specific -coil structure upon receptor
binding followed by an -helical structure of residues 8–21
(44). The relevance of the receptor-boundPACAP(1–21) struc-
ture for GLP-1 in particular is supported by a previous study of
FIGURE 5. Crystal packing. A, superposition of ECD-bound GLP-1 (blue) and exendin-4(9–39) (cyan). GLP-1
residue Gly22* denotes a kink in the -helix, which is situated in close proximity to Leu32 of the ECD. B, crystal
packing involving symmetry-related complexmolecules. C, ribbon diagram of GLP-1 (blue) and its interactions
with the ligandof a symmetry-relatedmolecule. Residues Tyr19*, Gln23*, andGlu27* are shownas sticks, and the
surface of the GLP-1R ECD is shown in gray. The packing of complex molecules allows Tyr19* to interact with
Gln23* (3 Å) and Glu27* (2.5 Å) in a symmetry-related ligand molecule. D, interactions between GLP-1 and
residues of symmetry-related ECD molecules. GLP-1 residues Thr11*, Thr
13*, Ser14*, and Glu21* are shown as
sticks. The backbone carbonyl of Thr11* could form a weak hydrogen bond (3.2 Å) to the backbone amide of
Gln112, the backbone amide of Thr13* could form a hydrogen bond (2.9 Å) to the backbone carbonyl of Gln112,
and the backbone amide of Ser14* may form a hydrogen bond (3 Å) to the side chain of Asp114. The side chain
of Glu21* forms a hydrogen bond to the backbone amide of Phe80 (2.6 Å).
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chimeric PACAP/GLP-1 peptides (45). Substituting five resi-
dues from the N-terminus of GLP-1 with those of PACAP (three
nonconserved, Fig. 1B) had no effect on either the affinity or
potency for GLP-1R. Thus, on the basis of both sequence
homology and structure-activity, GLP-1 would be expected to
adopt a similar conformation upon binding to the GLP-1R TM
domain.
Conclusion—The crystal structure presented here shows
the molecular details of GLP-1 binding to the GLP-1R ECD,
an essential step in the two-domain binding mechanism of
GLP-1R and class B GPCRs in general. Collectively, results
from structural characterization of GLP-1 in solution, struc-
ture-activity analyses ofGLP-1 analogues, and the crystal struc-
ture of GLP-1 bound to the GLP-1R ECD presented here sug-
gest that GLP-1 is a continuous -helix from Thr13* to Val33*
when bound to the full-lengthGLP-1R. This is important infor-
mation for the design of peptide therapeutics targeting GLP-
1R. GLP-1 and exendin-4 share the same binding site of the
GLP-1R ECD, but the ligand-specific effects on the ECD struc-
ture and the ligand-specific effects of receptor mutagenesis
support the existence of differences in the binding modes of
GLP-1 and exendin-4 to the full-length GLP-1R. The nature of
these differences as well as the active conformation of peptide
agonists (kinked or not) and a better understanding of the two-
domain binding mechanism await structural characterization
of the full-length GLP-1R.
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Study II – Small molecule mediated activation of GLP-1R 
A small part of the thesis work focused on identifying receptor domains important for small 
molecule-mediated activation of GLP-1R. The results of this work suggested that TM2 and TM7 
are involved in small molecule-mediated activation of GLP-1R and specifically Thr391 in TM7 
seems to play an important role. The work was published in Pharmacology in 2011. 
 
 
Figure 14. Chemical structure of Compound 3. Compound 3 is structurally related to Compound 2 (Figure 11A), 
although Compound 3 acts as a partial agonist in stimulating a cAMP response from GLP-1R, whereas Compound 2 
acts as a full agonist. The agonistic and allosteric properties of Compound 2 have been described in a number of 
papers (194;213;231). 
Compound 3 is based on a quinoxaline scaffold (Figure 14), which was initially identified in a 
functional screening of ~ 250.000 compounds (213). In Study II, we found that Compound 3 
selectively activated GLP-1R, but not the homologous GCGR. This receptor selectivity of 
Compound 3 encouraged a chimeric receptor approach to localise the domain of action for 
Compound 3. The results pointed to a functional importance of the segment defined by TM2 to 
TM5. Consequently, site-directed mutagenesis was employed to identify specific residues 
involved in Compound 3 action. The majority of the experimental work was carried out before 
crystal structures were available for ligand-activated GPCRs. Hence, a three-dimensional model 
structure of GLP-1R published by Frimurer & Bywater (232) was used to select specific 
residues for site-directed mutagenesis. According to this model, the side chains of Leu192 
(TM2), Phe195 (TM2) and Leu278 (TM4) face the plasma membrane (232), so these three 
residues were included as control mutations. The model predicts that the side chains of Tyr241 
(TM3) and Thr391 (TM7) point towards residues in other TM helices (232), so Tyr241 and Thr391 
were changed to Ala. We found that Tyr241 and Thr391 were indeed involved in Compound 3-
mediated activation of GLP-1R, as mutation to Ala significantly decreased the potency and 
efficacy of Compound 3 without affecting GLP-1 potency or affinity (Kd = 0.21 ± 0.02 nM for 
GLP-1 on wild-type GLP-1R compared to 0.18 ± 0.02 nM and 0.19 ± 0.02 nM on Tyr241-Ala and 
Thr391-Ala GLP-1R, respectively). Interestingly, two new model structures of GLP-1R have 
recently been published. The structure published by Coopman et al. predicts that the side 
chains of Tyr241 and Thr391 are orientated toward each other in the centre of the helical bundle 
(179), which is supported by our observations. The other model structure, which was recently 
published by Kirkpatrick et al., predicts that Thr391 interacts directly with His1 of exendin-4 
(233). Our findings suggest that Thr391 is not important for GLP-1 binding to GLP-1R. However, 
several studies support the existence of different binding modes of GLP-1 and exendin-4 to the 
TM domain of GLP-1R (63;182;189), so mutation of Thr391 may have differential effects on 
GLP-1 and exendin-4 binding.  
The experimental work included in Study II was done mainly by Steffen Reedtz-Runge, who 
constructed the chimeric- and mutant receptors and performed the functional studies. I 
performed the saturation binding experiments and wrote the manuscript.  
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The molecular basis for Compound 2 action 
The binding sites of several family B small molecule ligands have been mapped (204-
206;215;234), but less is known about the structural basis for their action. Extensive 
truncation of the calcitonin receptor ECD combined with site-directed mutagenesis showed that 
residues on the border between the ECD and TM1 are important for small molecule action at 
this receptor (235). This was the only study that specifically identified functionally critical 
residues for a small molecule agonist of a family B GPCR, until Study II was published. The 
agonistic and allosteric properties of Compound 2 have been investigated in more detail than 
those of Compound 3. Still, the molecular basis for Compound 2 action is unknown. Sexton et 
al. recently showed that ECL2 is important for GLP-1 binding and GLP-1 mediated activation of 
GLP-1R, but not for Compound 2 (236). A subsequent study of the functional effects of GLP-1R 
single nucleotide polymorphisms (SNPs) identified a single amino acid substitution Ser333 → Cys 
in ICL3 that specifically abolished Compound 2-mediated signalling through Gs without 
affecting peptide ligand-mediated signalling (237). The molecular basis for this observation 
was not investigated further, so the binding pocket of Compound 2 and the molecular basis for 
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meric receptors suggested that the existence of a helix-helix 
interface between TM1 and TM7 is important for the com-
pound 3 response. Furthermore, site-directed mutagenesis 
revealed that a Phe195-Leu substitution in TM2 and a Thr391-
Ala substitution in TM7 increased and decreased the efficacy 
of compound 3 without disturbing the potency or efficacy 
of GLP-1. Collectively, differential effects of receptor muta-
tions suggest that TM2 and/or TM7 are important for com-
pound 3-mediated activation of GLP-1R.
 Copyright © 2011 S. Karger AG, Basel
 Introduction
 Glucagon-like peptide 1 (GLP-1) binds and activates 
the GLP-1 receptor (GLP-1R) on pancreatic   -cells and 
potentiates insulin secretion in a glucose-dependent 
manner  [1–3] . Given its regulatory function in glucose 
homeostasis, GLP-1 has an obvious potential in the treat-
ment of type 2 diabetes and obesity. However, GLP-1 is 
quickly degraded in circulation by dipeptidyl peptidase-
 Key Words
 G-protein coupled receptor   Small molecule agonist   
cAMP   Mutagenesis
 Abstract
 Glucagon-like peptide-1 (GLP-1) activates the GLP-1 receptor 
(GLP-1R), which belongs to family B of the G-protein-coupled 
receptors. We previously identified a selective small mole-
cule ligand, compound 2, that acted as a full agonist and al-
losteric modulator of GLP-1R. In this study, the structurally 
related small molecule, compound 3, stimulated cAMP pro-
duction from GLP-1R, but not from the homologous gluca-
gon receptor (GluR). The receptor selectivity encouraged a 
chimeric receptor approach to identify domains important 
for compound 3-mediated activation of GLP-1R. A subseg-
ment of the GLP-1R transmembrane domain containing TM2 
to TM5 was sufficient to transfer compound 3 responsive-
ness to GluR. Therefore, divergent residues in this subseg-
ment of GLP-1R and GluR are responsible for the receptor 
selectivity of compound 3. Functional analyses of other chi-
 Received: October 11, 2011
 Accepted: October 12, 2011




 Novo Nordisk Park G8.S.439
 DK–2760 Maaloev (Denmark)
 Tel. +45 3075 4431, E-Mail sffr   @   novonordisk.com 
 © 2011 S. Karger AG, Basel
 0031–7012/11/0886–0340$38.00/0 
 Accessible online at:
 www.karger.com/pha 
Activation of GLP-1 Receptor Pharmacology 2011;88:340–348 341
IV (DPPIV). One approach to circumvent the short half-
life of GLP-1 in plasma is to make albumin binding ana-
logues like liraglutide. Liraglutide is an acylated GLP-1 
analogue with long-acting biological activity, which pos-
sesses all the beneficial effects of native GLP-1  [4, 5] . Pep-
tide-based GLP-1 analogues like liraglutide are adminis-
tered by subcutaneous injection, but prospective develop-
ment of orally active pharmaceuticals has driven the 
search for small molecule agonists that target GLP-1R.
 GLP-1 acts through a G-protein-coupled receptor 
(GPCR). GPCRs can be divided phylogenetically into five 
main families; rhodopsin, secretin, glutamate, adhesion 
and frizzled/taste2 with GLP-1R belonging to the secretin 
family, also known as family B  [6] . This family includes a 
wide range of receptors for peptide hormones like gluca-
gon, glucagon-like peptide-2 (GLP-2), glucose-dependent 
insulinotropic polypeptide (GIP), pituitary adenylyl cy-
clase-activating polypeptide (PACAP), vasoactive intesti-
nal polypeptide (VIP), secretin, calcitonin, corticotro-
phin-releasing factor (CRF) and parathyroid hormone 
(PTH)  [6] . The most closely related receptors to GLP-1R 
are receptors for peptides of the glucagon branch (gluca-
gon, GLP-2 and GIP), with the highest identity found be-
tween GLP-1R and the glucagon receptor (GluR, 44%). 
 Structural information of family B GPCRs comes 
from crystal structures of ligand-bound N-terminal ex-
tracellular domains (ECDs)  [7–12] and from biochemical 
studies resulting in a two-domain binding model for pep-
tide ligands of family B GPCRs (reviewed in  [13] ). The 
ECD of the receptor interacts with the C-terminal part of 
the peptide, which in turn directs the N-terminal part of 
the peptide towards the TM domain. However, the activa-
tion site of the TM domain is poorly defined. A pair of 
polar residues in the second TM helix (TM2) is a con-
served feature among family B GPCRs, and they appear 
to be important for peptide agonist binding and activa-
tion of several family B receptors  [14–17] . Neighboring 
Arg and Ser residues make up a polar face in TM2 of GLP-
1R, which may provide a surface for interaction with ei-
ther GLP-1 or another TM helix during receptor activa-
tion. The latter is supported by site-directed mutagenesis 
studies on PTH receptor, which suggest that TM2 could 
be functionally linked to TM7 during ligand binding and 
activation  [18, 19] . Similarly, a recent study that combined 
molecular modeling and site-directed mutagenesis of the 
human VPAC1 receptor, demonstrated that interactions 
between specific residues in TM2, TM3 and TM7 are im-
portant for activation of the receptor  [20] . Site-directed 
mutagenesis of a highly conserved His in the cytoplasmic 
end of TM2 (His180 in GLP-1R) induced constitutive ac-
tivity of many family B GPCRs and a point mutation in 
the cytoplasmic end of TM7-induced constitutive activity 
of PTH receptor  [21–25] . Collectively, these results em-
phasize TM2 and TM7 as potentially important regions 
for activation of family B GPCRs. 
 Potential binding sites have been identified for several 
small molecule ligands that target family B receptors  [26–
32] . A single residue in the ECD of the human GLP-1R 
(Trp33) was shown to be responsible for the species selec-
tivity (human/rat) of a small molecule GLP-1R antagonist 
 [32] . Likewise, the competitive antagonist olcegepant 
binds to the calcitonin gene-related peptide (CGRP) re-
ceptor ECD as demonstrated by X-ray crystallography 
 [33] . However, residues in the extracellular end of TM3 
and TM5 may determine receptor-subtype selectivity of 
a small molecule antagonist of the CRF1 receptor  [31] . 
Site-directed mutagenesis of several residues in the TM 
domain of the rat GluR identified residues in TM2 and 
TM3, whose substitution with alanine decreased the 
binding affinity of a small molecule GluR antagonist, 
while preserving glucagon binding  [26] . Thus, small mol-
ecule antagonists of family B GPCRs could bind either 
the ECD or in the TM domain and thereby compete for 
peptide agonist binding. On the contrary, small molecule 
agonists probably have to bind to the TM domain or the 
extracellular loops (ECLs) in order to activate the recep-
tor. Several small molecule agonists have been identified 
that activate GLP-1R  [27, 30, 34] ( fig. 1 ). Screening of a 
compound library identified a small molecule that stimu-
lated cAMP production in transfected BHK cells express-
ing GLP-1R  [30] . Subsequent optimization generated a 
full agonist, compound 2 ( fig. 1 ), that stimulated cAMP 
production with an EC50 value of 101  8 21 nmol/l in 
transfected BHK cells expressing GLP-1R  [30] . In more 
physiological settings, compound 2 potentiated insulin 
secretion from isolated mouse pancreatic islets in a 
 glucose-dependent manner, whereas neither GLP-1 nor 
compound 2 potentiated insulin secretion from islets of 
GLP-1R knockout mice  [30] . Other small molecule ago-
nists, like Boc5 ( fig. 1 ) and compound B ( fig. 1 ), have been 
identified that mimic the effects of GLP-1 in vitro and in 
vivo  [27, 34] . A three-dimensional model structure of 
GLP-1R was used to predict the putative binding site of 
Boc5 to be located near the extracellular end of TM3 and 
TM4  [35] . However, it is worth noting that the agonistic 
effect of Boc5, but not the agonistic effect of compound 2 
or compound B, was blocked by the selective GLP-1R an-
tagonist exendin-(9–39)  [27, 30, 34] . In addition, com-
pound 2 allosterically increased the binding affinity of 
GLP-1 for GLP-1R  [30] . Hence, it appears that Boc5 binds 
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to the orthosteric binding site, whereas compound 2 and 
compound B bind to an allosteric site in GLP-1R. 
 The small molecule compound 3 is structurally related 
to compound 2 ( fig. 1 ) and it selectively activated the hu-
man GLP-1R, but not the homologous human GluR in 
transfected human embryonic kidney (HEK) 293 cells. 
Compound 3 acted as a partial agonist of GLP-1R. The 
receptor selectivity of compound 3 encouraged a chime-
ric receptor approach to identify domains that are im-
portant for compound 3-mediated activation of GLP-1R. 
Site-directed mutagenesis subsequently identified single 
residues in TM2, TM3 and TM7 of GLP-1R that specifi-




 The cDNAs encoding the human GLP-1R and the human 
GluR were originally obtained from Dr. B. Thorens and Zymoge-
netics Inc. (Seattle, Wash., USA) and subcloned into the mamma-
lian expression vector pcDNA3.1/V5-His-TOPO  (Invitrogen, 
Taastrup, Denmark)  [36, 37] . The chimeric glucagon/GLP-1 re-
ceptors chimera A and chimera B were generated in previous 
studies  [38] . Chimera A was composed of amino acid residues 
1–144 of GluR and residues 148–463 of GLP-1R, chimera B was 
composed of residues 1–169 and 346–477 of GluR and residues 
173–347 of GLP-1R. The new chimeric glucagon/GLP-1 receptor 
chimera C was generated by overlap extension PCR, as previously 
described and was composed of residues 1–169 of GluR and 
 residues 173–463 of GLP-1R  [38] . Site-directed mutagenesis of 
GLP-1R was done using QuickChange TM  (Agilent Technologies, 
Hoersholm, Denmark) and plasmid DNA was generated and se-
quenced as previously described  [38] . 
 Chemical Synthesis of Peptides and Compound 3
 Glucagon, GLP-1 (7–37),  125 I-GLP-1(7–36)amide and com-
pound 3 were synthesized and characterized as previously de-
scribed  [30, 38] . 
 Cell Culture and Transient Receptor Expression
 HEK293 cells were maintained in Dulbecco’s modified Eagle’s 
medium supplemented with 10% fetal bovine serum and penicil-
lin/streptomycin (90 U/ml and 90   g/ml, respectively) (Invitro-
gen). Cells were seeded in T75 flasks, transfected with 9   g of 
DNA using the FuGene TM  transfection reagent (Roche, Hvidovre, 
Denmark), harvested 24 h after transfection and used directly in 
functional experiments or plasma membrane preparations as de-
scribed previously  [38] .
 Functional Assay
 HEK293 cells transiently expressing the desired wild type, 
mutant or chimeric receptor were resuspended in assay buffer 
containing 3-isobutyl-1-methylxanthine (IBMX) (Flashplate  , 
Perkin Elmer, Skovlunde, Denmark) to a cell density of 2  ! 10 6  
cells/ml. GLP-1 and glucagon were dissolved and diluted in 0.02% 
Tween-20, 1% dimethylsufoxide (DMSO). 
 Compound 3 was initially dissolved in 100% DMSO and di-
luted to 1% DMSO in 0.02% Tween-20. Cells in assay buffer (50 
  l) and GLP-1, glucagon or compound 3 (50   l) were mixed in 
96-well Flashplates (Perkin Elmer), gently agitated for 5 min and 
incubated for 25 min at room temperature. The resulting intracel-
lular level of cAMP was measured according to supplier’s manual 
and data were analyzed by nonlinear regression analysis using 
Prism  (GraphPad Software, Inc., La Jolla, Calif., USA). Statisti-
cal analyses were performed in Prism using the unpaired t test. 
 Saturation Binding Assay
 Freshly thawed plasma membrane preparations from tran-
siently transfected HEK293 cells expressing wild-type GLP-1R or 
GLP-1R mutants were pulled through a 25-gauge needle three 
times and diluted in assay buffer (50 mmol/l HEPES, 5 mmol/l 
MgCl 2 , 5 mmol/l EGTA, 0.005 vol% Tween-20, pH 7.4). Mem-
brane preparations ranged between 0.25–2   g protein/well. Dif-
ferent dilutions of the radioligand  125 I-GLP-1(7–36)amide were 
prepared in assay buffer corresponding to a concentration range 
of approximately 0.025–0.9 nmol/l. Nonspecific binding was de-
termined with 1   mol/l GLP-1. Membrane-preparation, GLP-1 
and radioligand were mixed in 96-well 0.65-  mol/l filter plates 














































 Fig. 1. Structures of small molecule agonists that target GLP-1R. 
Chemical structures of four GLP-1R agonists. Compound 3 (top 
left) is structurally related to compound 2 (top right  [30] ), where-
as Boc5 (bottom left  [27] ) and compound B (bottom right  [34] ) 
are based on different scaffolds. 
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37   °   C. Subsequently, bound and unbound radioligand were sepa-
rated by vacuum filtration (Millipore vacuum manifold). The fil-
ters were washed twice in 100   l cold assay buffer and left to dry. 
Data were fitted as one-site binding using Prism. Statistical anal-
yses were performed in Prism using the unpaired t test. 
 Results
 Glucagon and GLP-1 Receptors
 The small molecule compound 3 ( fig. 1 ) stimulated the 
production of cAMP in GLP-1R-expressing cells with 
EC 50  = 1.9  8 0.11   mol/l and with 42% efficacy relative 
to GLP-1 (100%) ( fig. 2 ;  table 1 ). Compound 3 was unable 
to stimulate cAMP production in GluR-expressing cells 
( fig. 2 ). This selectivity for the human GLP-1R encour-
aged a chimeric receptor approach to identify the do-
mains and residues that are important for compound 
3-mediated activation of GLP-1R.
 Chimeric Glucagon/GLP-1 Receptors
 Chimera A consists of the ECD of GluR and the TM 
domain of GLP-1R as described previously  [38] . The po-
tency of GLP-1 on chimera A was reduced   100-fold 
compared to wild-type GLP-1R. However, compound 3 
activated chimera A with EC 50  = 1.6  8 0.19   mol/l and 
with a relative efficacy of 48% ( table 1 ), which is compa-
rable to its potency and efficacy on wild-type GLP-1R. In 
order to narrow down the TM segments that determine 
compound 3 activity, compound 3 was analyzed for its 
ability to activate other more GluR-like chimeric recep-
tors. Chimera A was made more GluR-like by substitut-
ing TM1 with that of GluR, and the resulting chimeric 
receptor, chimera C, was analyzed in functional experi-
ments. Glucagon and GLP-1 activated chimera C with 
similar intracellular cAMP levels compared to chimera A 
( fig. 2 ), and the glucagon/GLP-1 selectivity profile of chi-
mera C was comparable to that of chimera A, although 
the potency of both peptides was reduced by   4-fold rel-
ative to chimera A. However, compound 3 was almost 
unable to activate chimera C ( fig. 2 ). The small molecule 
agonist was analyzed further for its ability to activate chi-
mera B, which is even more GluR-like compared to chi-
mera C. Surprisingly, compound 3 activated chimera B 
with EC 50  = 2.4  8 0.41   mol/l and an efficacy of 52% 
relative to glucagon (100%). 
 Site-Directed Mutagenesis of the GLP-1 Receptor
 The functional properties of chimera B indicated that 

















































































 Fig. 2. Stimulation of cAMP production of transfected HEK293 
cells transiently expressing GLP-1R, GluR or chimeric glucagon/
GLP-1 receptors by GLP-1, glucagon or compound 3. Each experi-
ment is representative of three or more independent experiments 
performed in duplicates. GLP-1-induced cAMP stimulation is 
shown by black curves and squares. Glucagon-induced cAMP stim-
ulation is shown by blue curves and open circles. Compound 3-in-
duced cAMP stimulation is shown by red curves and open triangles. 
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of GLP-1R are involved in compound 3-mediated activa-
tion. In our initial effort to identify single residues impor-
tant for compound 3-mediated activation and/or receptor 
selectivity, we mutated a few residues in TM2 and TM4 
based on the three-dimensional model structure of GLP-
1R published by Frimurer and Bywater  [39] . Three hydro-
phobic residues, Leu192 (TM2), Phe195 (TM2) and Leu278 
(TM4) were substituted with the corresponding Ser, Leu 
and Met of GluR, respectively ( fig. 3 ). Two additional res-
idues, Tyr241 (TM3) and Thr391 (TM7), were substituted 
with Ala based on the three-dimensional model structure 
of GLP-1R  [39] . GLP-1 and compound 3 were analyzed in 
parallel for their ability to stimulate cAMP production in 
transfected HEK293 cells transiently expressing GLP-1R 
 Table 1. F unctional properties of GLP-1R, GluR, chimeric glucagon/GLP-1 receptors and GLP-1R point mutants
 Receptor  E C 50  values  Relative, 
 efficacy a , % 
 B max , 
 fmol/mg  GLP-1, pmol/l  glucagon, pmol/l  compound 3,   mol/l 
 GLP-1R 21 8 2.1  21,000 8 4,600**  1.9 8 0.11  42 8 1.7  275 8 36 
 GluR  n.a. 27 8 6.3  n.a.  n.a. – 
 Chimera A  2,000 8 880** 23 8 3.5  1.6 8 0.19  48 8 2.0 – 
 Chimera C  7,500 8 2,200** 110 8 17**  n.a.  n.a. – 
 Chimera B  ≥100,000** 40 8 5.7  2.4 8 0.41  52 8 3.0 b,  ** – 
 Leu192-Ser 19 8 1.4 –  2.1 8 0.50  44 8 5.0 – 
 Phe195-Leu 19 8 4.3 –  0.67 8 0.09***  72 8 2.4***  163 8 7.0* 
 Tyr241-Ala 33 8 7.4 –  4.2 8 0.61***  25 8 1.5***  116 8 7.0* 
 Leu278-Met 26 8 7.5 –  1.8 8 0.35  37 8 2.4 – 
 Thr391-Ala 26 8 9.7 –  6.3 8 1.7***  15 8 1.1***  482 8 54* 
 All values represent mean  8 SEM of three or more independent experiments performed in duplicates. 
 a The relative efficacy is the maximal response of compound 3 relative to the maximal response of GLP-1 (100%). b The relative ef-
ficacy is the maximal response of compound 3 relative to glucagon.  B max  values were measured for GLP-1 only. The EC 50  values, rela-
tive efficacy and B max  values of GLP-1, glucagon and/or compound 3 at each chimera or receptor mutant were compared to those of 
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 Fig. 3. Stimulation of cAMP production of transfected HEK293 
cells transiently expressing GLP-1R or GLP-1R point mutants by 
GLP-1 or compound 3. All GLP-1R point mutants (illustrated in 
upper panel) were analyzed in parallel with GLP-1R and each ex-
periment is representative of three or more independent experi-
ments performed in duplicates. cAMP dose-response curves of 
GLP-1R – GLP-1: closed squares; compound 3: closed triangles. 
cAMP dose-response curves of GLP-1R point mutants – GLP-1: 
open circles; compound 3: open triangles. 
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or GLP-1R point mutants ( fig. 3 ). The apparent potency of 
GLP-1 and compound 3 and the efficacy of compound 3 
relative to GLP-1 are given in  table 1 . Wild-type GLP-1R 
and the Leu192-Ser and Leu278-Met GLP-1R mutants 
were activated with the same potency and relative efficacy 
by GLP-1 and compound 3 ( table 1 ). In contrast, the muta-
tions Phe195-Leu, Tyr241-Ala and Thr391-Ala signifi-
cantly altered the potency and efficacy of compound 3 
without disturbing the potency and efficacy of GLP-1 ( ta-
ble 1 ;  fig. 3 ). The relative efficacy of compound 3 was in-
creased to 72% for the Phe195-Leu GLP-1R mutant, com-
pared to 42% for wild-type GLP-1R (p  ! 0.0001). Simi-
larly, the potency of compound 3 was significantly 
increased to EC50 = 0.67  8 0.09   mol/l(p  ! 0.0001) com-
pared to wild-type GLP-1R. The expression level of the 
Phe195-Leu mutant was slightly decreased compared to 
wild-type GLP-1R (B max  = 163  8 7.0 fmol/mg compared 
to B max  = 275  8 36 fmol/mg, p = 0.02;  table 1 ). However, 
neither the potency nor the efficacy of GLP-1 was affected, 
which confirmed the structural integrity of the receptor 
mutant. The Tyr241-Ala and Thr391-Ala mutations sig-
nificantly decreased the efficacy of compound 3 to 25% 
(p = 0.0004) and 15% (p  ! 0.0001) relative to GLP-1. Simi-
larly, both mutations significantly decreased compound 3 
potency to EC 50  = 4.2  8 0.61   mol/l (p  ! 0.0001) and
EC 50  = 6.3  8 1.7   mol/l (p  ! 0.0001), respectively. The 
expression level of the Tyr241-Ala mutant was slightly de-
creased compared to wild-type GLP-1R (B max  = 116  8 7.0 
fmol/mg compared to B max  = 275  8 36 fmol/mg, p = 0.01; 
 table 1 ), whereas the expression level of the Thr391-Ala 
mutant was increased compared to wild-type GLP-1R 
(B max  = 482  8 54 fmol/mg compared to B max  = 275  8 36 
fmol/mg, p = 0.03;  table 1 ). 
 Discussion
 Several small molecule agonists have been identified 
for GLP-1R  [27, 30, 34] , yet little is known about their site 
of interaction with the receptor. We previously identified 
a selective small molecule ligand, compound 2, that acted 
as a full agonist and allosteric modulator of GLP-1R  [30] . 
In this study, the structurally related small molecule, 
compound 3, stimulated cAMP production from GLP-
1R, but not from the homologous glucagon receptor 
(GluR). This selectivity for the human GLP-1R encour-
aged a chimeric receptor approach to identify the do-
mains and residues that are important for compound 
3-mediated activation of GLP-1R.
 The GLP-1R ECD determines specificity for the C-ter-
minal part of GLP-1, and it is the primary determinant of 
the glucagon/GLP-1 selectivity profile of GLP-1R (differ-
ence in affinity/potency of glucagon and GLP-1)  [38] . In 
contrast, the GLP-1R TM domain is much less selective 
and interacts almost equally well with the N-terminal 
part of GLP-1 and glucagon. Chimera A was constructed 
for a previous study  [38] and consists of the ECD of GluR 
and the TM domain of GLP-1R. The potency of GLP-1 on 
chimera A was reduced significantly compared to wild-
type GLP-1R, whereas the potency and efficacy of com-
pound 3 on chimera A was comparable to those of wild-
type GLP-1R. Based on this result, it seems likely that 
compound 3 binds to the TM domain of GLP-1R and that 
the residues responsible for compound 3-mediated acti-
vation of GLP-1R are present in the TM domain. 
 In order to narrow down the TM segments that deter-
mine compound 3 activity, compound 3 was analyzed for 
its ability to activate other more GluR-like chimeric re-
ceptors. Chimera C consists of the ECD and TM1 of GluR 
and TM2-TM7 of GLP-1R. The glucagon/GLP-1 selectiv-
ity profile of chimera C was comparable to that of chi-
mera A, but compound 3 was almost unable to activate 
chimera C. Hence, at this point it seemed that TM1 was 
very important for compound 3-mediated activation of 
chimera A. Compound 3 was subsequently analysed for 
its ability to activate chimera B, which was initially char-
acterized in a previous study  [38] and has a stronger glu-
cagon/GLP-1 selectivity profile than chimera A because 
of additional selectivity determinants in the GluR TM 
domain. Surprisingly, the negative impact of TM1 of 
GluR on compound 3-mediated activation of chimera C 
was rescued by adding TM6 and TM7 of GluR, regardless 
of the loss of potency of GLP-1 relative to glucagon. The 
rescue of the compound 3 response of chimera B is prob-
ably best explained by the existence of a helix-helix inter-
face between TM1 and TM7. Accordingly, some degree of 
molecular incompatibility between TM1 and TM7 of chi-
mera C eliminated the compound 3 response while pre-
serving almost entirely the glucagon/GLP-1 selectivity 
profile and potency. The molecular incompatibility prob-
ably destabilized the active conformation obtained by 
compound 3 and/or directly affected the binding of com-
pound 3. We cannot distinguish between these two pos-
sibilities. Nevertheless, the GLP-1R segment of chimera B 
(TM2 to TM5 and connecting loops) was sufficient to 
transfer compound 3 responsiveness to GluR and there-
fore divergent residues within this segment are important 
for compound 3-mediated activation. 
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 In the beta-2-adrenergic receptor, a family A GPCR, 
intramolecular hydrogen bonds link amino acid side 
chains in TM2 and TM7  [40, 41] , in analogy with the 
functional coupling of TM2 and TM7 of the PTH recep-
tor and the VPAC1 receptor  [18–20, 42] . The proximity of 
TM2 and TM7 of GluR probably accommodates the glu-
cagon N-terminus as shown previously  [43] and the res-
cue of the compound 3 response by chimera B suggests 
that a functionally important interface exists between 
TM1 and TM7. Collectively, previous studies combined 
with our data indicate that TM1, TM2 and TM7 close up 
the 7TM helical bundle of family B 7TM GPCRs in anal-
ogy with the overall arrangement of the 7TM helices of 
family A GPCRs. 
 The functional properties of chimera B indicated that 
residues within TM2-TM5 of GLP-1R are involved in 
compound 3-mediated activation. Based on the model 
structure of GLP-1R used to predict the putative binding 
site of Boc5  [35] , it seems likely that residues in the extra-
cellular end of TM2-TM5 are important for the small 
molecule mediated response. However, it was beyond the 
scope of this study to systematically investigate all the di-
vergent residues within this region. We mutated a few 
residues in TM2, TM3, TM4 and TM7 based on the three-
dimensional model structure of GLP-1R published by 
Frimurer and Bywater  [39] . According to this model, the 
side chains of Leu192 (TM2), Phe195 (TM2) and Leu278 
(TM4) face the plasma membrane  [39] , so mutation of 
these three residues was included as a negative control. 
The side chains of Tyr241 (TM3, conserved in GLP-1R 
and GluR) and Thr391 (TM7, Ser389 in GluR) could point 
towards potential small molecule binding sites  [39] ,
so Tyr241 and Thr391 were substituted with Ala. The 
Thr391-Ala substitution was included to further investi-
gate the importance of TM7 in compound 3-mediated 
activation of GLP-1R. The Phe195-Leu, Tyr241-Ala and 
Thr391-Ala mutations significantly altered the potency 
and efficacy of compound 3 without disturbing the po-
tency and efficacy of GLP-1. This corresponds well with 
the observation made by Coopman et al. [44] who recent-
ly showed that the Thr391-Ala mutation does not affect 
GLP-1 affinity or potency. Surprisingly, the relative effi-
cacy and potency of compound 3 was increased for the 
Phe195-Leu mutant compared to wild-type GLP-1R de-
spite a decrease in receptor expression level. However, 
neither the potency, nor the efficacy of GLP-1 was affect-
ed, which confirmed the structural integrity of this re-
ceptor mutant. Interestingly, the model structure of GLP-
1R used to predict the putative binding site of Boc5  [35] 
shows that the side chain of Phe195 is positioned near the 
binding site of Boc5 in the interface between TM2 and 
TM7. The most recent model structure of GLP-1R pre-
dicts a slightly different position of Phe195, i.e. in the in-
terface between TM1 and TM2  [44] ( fig. 4 ). Hence, our 
results support the existence of a functional interface be-
tween TM1, TM2 and TM7 in GLP-1R, and Leu195 may 
either facilitate conversion between inactive and active 
receptor conformations or stabilize active conformations 
 Fig. 4. Helical wheel diagram of GLP-1R. 
The helical wheel diagram represents the 
central 18 residues in each helix according 
to the most recent GLP-1R model  [44] . In 
this study, Leu192 (TM2), Phe195 (TM2) 
and Leu278 (TM4) (highlighted in grey) 
were substituted with the corresponding 
Ser, Leu and Met of GluR, respectively. 
Tyr241 (TM3) and Thr391 (TM7) (also 
highlighted in grey) were substituted with 
Ala. 
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Study III – A Cysteine-deprived and C-terminally truncated GLP-1R 
In 2002, Rudolph et al. developed a method to express, purify and refold the GLP-1R ECD 
(172). This marked the starting point of a year-long collaboration between Novo Nordisk and 
the group of Prof. Rainer Rudolph at the Martin Luther University in Halle, Germany. Part of the 
collaboration focused on expressing the full-length GLP-1R in E. coli inclusion bodies as well as 
developing techniques to solubilise and refold the receptor. The work included in Study III 
aimed to simplify the refolding process by modifying GLP-1R by site-directed mutagenesis. 
Several cysteine-deprived and/or C-terminally truncated GLP-1Rs were constructed. Functional 
characterisation of these receptors combined with binding experiments showed that seven 
cysteine residues and more than half of the C-terminal tail are not required for GLP-1 binding 
or function (Figure 15). I undertook all the experimental work included in Study III and wrote 
the manuscript. The manuscript will be submitted to ‘Peptides’ in the near future. 
 
Figure 15. A fully functional cysteine-deprived and C-terminally truncated GLP-1R. Study III describes the 
development and characterisation of a cysteine-deprived and C-terminally truncated GLP-1R. The ‘Cys 11-426’ mutant 
shown above contains four Cys-Ala substitutions (Cys236-Ala, Cys329-Ala, Cys341-Ala and Cys347-Ala) and lacks the last 
37 amino acids of the C-terminal tail. The affinity and potency of GLP-1 is similar for ‘Cys 11-426’ compared to wild-type 
GLP-1R. Three cysteines in the distal part of the C-terminal tail can also be changed to Ala without compromising GLP-
1 function or binding. The putative signal sequence is shown in grey. 
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Challenges in GPCR crystallography 
Until recently, our understanding of GPCR structure was based mainly on the crystal structures 
of the inactive state of rhodopsin (118;238;239). Rhodopsin is more stable than ligand-
activated GPCRs, and it is possible to obtain large quantities of the receptor from natural 
sources. Other GPCRs are expressed at relatively low levels in native tissues, so efficient 
expression systems are required to produce large quantities of recombinant receptors. Also, 
ligand-activated GPCRs contain unstructured regions and cycle between inactive- and active 
states, which decreases stability even further. In addition, most GPCRs are unstable in 
detergent, which severely limits the crystallisation conditions. To overcome these changes, all 
the GPCRs crystallised since rhodopsin have been modified by site-directed mutagenesis. 
Modifications include thermostabilising mutations (126), truncation of the receptor C-terminal 
(123;126;130), removed glycosylation sites (130) and mutations that increase the expression 
level of the receptor (130). In addition, the conformational stability of the GPCRs has been 
improved by means of ligand binding (122-125;130), T4L fusion (124;125;129;240) and 
binding of various antibodies (123;128;130). These structural modifications have contributed 
to the recent advances in GPCR crystallography. 
Over the years, E. coli has been widely used for expression of recombinant proteins that do not 
require post-translational modifications (241). However, high expression of recombinant 
proteins in E. coli often leads to accumulation of the protein of interest into insoluble 
aggregates known as inclusion bodies. Inclusion body proteins are misfolded and devoid of 
biological activity, so elaborate solubilisation, refolding and purification procedures are 
required to obtain a fully functional protein (242). During the refolding process, misfolded 
proteins and protein aggregates can hamper the recovery of correctly folded proteins (242). 
Formation of random intra- and intermolecular disulphide bonds can lead to misfolding of the 
protein. Hence, a cysteine-deprived form of the protein of interest is desirable, as it may 
increase the yield of correctly folded protein. 
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Abstract 
The glucagon-like peptide-1 receptor (GLP-1R) belongs to family B of the G-protein coupled 
receptors (GPCRs), and has become a promising target for the treatment of type 2 diabetes. 
Here we describe the development and characterization of a fully functional cysteine-deprived 
and C-terminally truncated GLP-1R. Single cysteines were initially substituted with alanine, and 
functionally redundant cysteines were subsequently changed simultaneously. The results 
indicate that Cys174, Cys226, Cys296 and Cys403 are important for the GLP-1-mediated response, 
whereas Cys236, Cys329, Cys341, Cys347, Cys438, Cys458 and Cys462 are not. Extensive deletions 
were made in the C-terminal tail of GLP-1R in order to determine the limit for truncation. We 
observed a direct correlation between the length of the C-terminal tail and specific binding of 
125I-GLP-1, indicating that the membrane proximal part of the C-terminal is involved in 
receptor expression at the cell surface. The results show for the first time that seven cysteines 
and more than half of the C-terminal tail can be removed from GLP-1R simultaneously without 
compromising GLP-1 binding or function. 
  
1. Introduction 
Glucagon-like peptide-1 (GLP-1)1 is a peptide hormone, which is released from intestinal L-
cells in response to food intake [1;2]. GLP-1 stimulates the synthesis and release of insulin 
from pancreatic β-cells in a glucose-dependent manner [3]. In addition, GLP-1 has a number 
of physiological effects that contribute to reducing blood sugar and body weight including 
inhibition of glucagon secretion [4;5] and gastric emptying [6;7], and reduction of food intake 
[8-10]. Hence, GLP-1-based therapies are becoming increasingly attractive for the treatment 
of type 2 diabetes. The actions of GLP-1 are mediated through the GLP-1 receptor (GLP-1R), 
which is a G protein-coupled receptor (GPCR). The human GLP-1R was first cloned in 1992 and 
belongs to family B of the GPCRs [11]. GPCRs belonging to family B are distinguished by their 
large extracellular N-terminal domain (ECD) which is important for ligand binding and 
selectivity [12;13]. The structure of the isolated ECD has been solved for several family B 
GPCRs with or without receptor-bound ligand. The structures include the ECD of type-1 
corticotrophin-releasing factor receptor (CRFR1) [14], the type-1 pituitary adenylate cyclase-
activating polypeptide receptor (PAC1-R) [15], the glucose-dependent insulinotropic 
polypeptide receptor (GIP-R) [16], GLP-1R [17;18], the glucagon receptor (GCGR) [19] and 
the type-1 parathyroid hormone receptor (PTH-1R) [20].  
The tertiary structure of GLP-1R ECD is stabilized by three conserved disulfide bonds and by 
several intramolecular interactions [17]. Hence, the six cysteines within the ECD are essential 
for the structure and function of GLP-1R. The GLP-1R contains a total of seventeen cysteine 
residues of which six reside in the ECD. The remaining eleven cysteines are found in the 
transmembrane (TM) helices, the loops and in the intracellular C-terminal tail (Figure 1). The 
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function and importance of some of these cysteines has been investigated by site-directed 
mutagenesis. For instance, it was recently shown that Cys226 in the first extracellular loop 
(ECL1) most likely forms a disulfide bond with Cys296 in ECL2 of GLP-1R. A disulfide bond has 
been located in the same topological position in several family A GPCRs, where it seems to be 
important for cell surface expression and ligand binding [21-23]. The existence of a disulfide 
bond between cysteines in ECL1/TM3 and ECL2 has also been proposed for other family B 
GPCRs including the vasoactive intestinal polypeptide (VIP) receptor [24] and the PTH-1R [25]. 
Substitution of Cys174 with Ala in the first intracellular loop (ICL1) of GLP-1R has been shown 
to reduce GLP-1 efficacy and receptor expression levels [26]. Similarly, a Cys438-Ala 
substitution in the C-terminal tail of GLP-1R significantly reduced GLP-1 efficacy although the 
expression level of the receptor was increased [27]. Of all the Cys-Ala substitutions reported 
for GLP-1R, only a Cys329-Ala mutation in TM5/ICL3 showed no reduction in receptor 
expression level or GLP-1-mediated response [26]. Hence, Cys329 is currently the only 
redundant cysteine residue reported for GLP-1R. 
It has been shown for several family A GPCRs that truncation of the C-terminal tail can 
improve receptor stability. A combination of C-terminal truncation and other sequence 
modifications have been applied to family A GPCRs, which ultimately facilitated crystallization 
of the TM domain of these receptors [28-30]. Fluorescence resonance energy transfer (FRET) 
based studies have shown that the C-terminal tail and ICL3 are the most unstructured regions 
of the β2-adreneric receptor (β2AR) [31]. Hence, the last 48 amino acids were removed from 
the C-terminal of β2AR, and two different approaches were employed to stabilize ICL3 in the 
first crystal structures of the inactive conformation of this receptor [28;32]. Similarly, more 
than 100 amino acids were removed from the C-terminal tail of the turkey β1-adreneric 
receptor (β1AR) and several mutations and deletions were introduced to facilitate 
crystallization of this receptor in complex with the high affinity antagonist cyanopindolol [29]. 
Preceding studies had shown that C-terminal truncation of β1AR increased receptor expression 
levels in Sf9 insect cells as well as HEK293 mammalian cells, and the truncated receptors were 
readily solubilized from the membrane compared to the wild-type receptor [33]. Such 
comprehensive studies of the C-terminal tail have not been reported for GLP-1R. However, 
truncation experiments indicate that the distal part of GLP-1R C-terminal is not involved in the 
signal transduction process [34], and similar observations have been made for other family B 
GPCRs [35;36]. Instead, phosphorylation of three serine doublets in the distal part of the C-
terminal (Ser441/Ser442, Ser444/Ser445 and Ser451/Ser452) appears to be important for 
desensitisation and internalisation of GLP-1R [37].   
The aim of the work described in this paper was to develop a fully functional cysteine-deprived 
and C-terminally truncated GLP-1R. The results show for the first time that seven cysteine 
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residues in GLP-1R and more than half of the C-terminal tail are not required for GLP-1 binding 
or function. 
 
2. Material and methods 
Receptor constructs - cDNA encoding human GLP-1R was originally obtained from Dr. B. 
Thorens [11] and subcloned into the mammalian expression vector pcDNA3.1/v5-His-TOPO® 
(Invitrogen). The presence of the C-terminal His6-tag was previously shown not to influence 
the functional response of the receptor [13]. Site-directed mutagenesis of GLP-1R was done 
using QuikChangeTM (Stratagene). The cysteine-deprived GLP-1R, Cys1, contained seven Cys-
Ala mutations (Cys236-Ala, Cys329-Ala, Cys341-Ala, Cys347-Ala, Cys438-Ala, Cys458-Ala and Cys462-
Ala). The cDNA sequence encoding Cys1 was purchased from GenScript Inc. (New Jersey, 
USA), and subcloned into pcDNA3.1/v5-His-TOPO®. Cys2, Cys3 and Cys4 were prepared from 
Cys1 by introducing an additional Cys174-Ala, Cys403-Ala or Cys174-Ala:Cys403-Ala double 
mutation, respectively. Plasmid DNA was generated using the NucleoBond® Xtra Maxi Plus kit 
(Macherey-Nagel), and the desired mutations were confirmed by sequencing (Eurofins MWG 
Operon, Germany). 
Cell Culture and Protein Expression– HEK293 cells were maintained in Dulbecco’s modified 
Eagles medium (BioWhittaker) supplemented with 10 vol-% fetal bovine serum (FBS) and 1 
vol-% penicillin/streptomycin (100 units/ml) in T-175 flasks (Nunc). HEK293 cells were 
transiently transfected with 21 µg wild-type or mutant GLP-1R DNA using the FuGENETM 
transfection reagent (Roche Applied Science). Cells were harvested 24 hours after transfection 
and used directly in functional experiments or plasma membrane preparations as previously 
described [13]. 
Functional Assay- Transiently transfected HEK293 cells expressing wild-type or mutant GLP-1R 
were harvested and resuspended in assay buffer incl. IBMX (Flashplate®, Perkin Elmer) to a 
cell density of 2.4 x 106 cells/ml. GLP-1(7-37)-acid was diluted in phosphate buffered saline 
(PBS) supplemented with 0.02 vol-% Tween-20, and the concentration ranged from 10 fM to 1 
nM. Cells in assay buffer (50 μl) and GLP-1 (50 μl) were mixed in 96-well FlashPlates® (Perkin 
Elmer), gently agitated for 5 minutes and incubated for 25 minutes at room temperature. The 
resulting intracellular level of cAMP was measured according to supplier’s manual and analyzed 
by non-linear regression/sigmoidal dose-response fitting using Prism 5.0® (GraphPad Software, 
Inc.).  
Receptor Binding Assay- Freshly thawed plasma membrane preparations from transiently 
transfected HEK293 cells expressing wild-type or mutant GLP-1R were pulled through a 25-
gauge needle three times and diluted in assay buffer (50 mM HEPES, 5 mM MgCl2, 5 mM EGTA, 
0.005 vol-% Tween-20, pH 7.4). GLP-1(7-37)-acid was diluted in assay buffer, and the 
concentration ranged from 1 pM to 100 nM. 125I-GLP-1 (7-36)-amide (2.2 Ci/μmol) was 
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dissolved in assay buffer and added at ~ 50,000 cpm per well corresponding to a final 
concentration of 50 pM. Nonspecific binding was determined using 1 µM unlabeled GLP-1. 
Membrane-preparation and radioligand were mixed in 96-well 0.65 μm filter plates (Millipore) 
and incubated with GLP-1 for 2 hours at 30oC. Subsequently, bound and unbound radioligand 
were separated by vacuum filtration (Millipore vacuum manifold). The filters were washed 
twice in 100 μl cold assay buffer and left to dry. Data were analyzed by non-linear regression 
using Prism 5.0® (GraphPad Software, Inc.). Statistical analyses were also performed in Prism 
5.0® using the unpaired t-test. 
 
3. Results 
3.1 Substitution of single cysteines 
The GLP-1R contains eleven cysteine residues in the TM domain and C-terminal tail. We 
substituted ten of these cysteines with alanine (Cys174 was changed to both Ala and Ser) in 
order to determine their functional redundancy in GLP-1R. The mutant GLP-1Rs were 
characterized by their ability to stimulate cAMP production in response to GLP-1 (Table 1). We 
found that six of the ten Cys-Ala substitutions had no significant negative effect on the GLP-1-
mediated response. Several substitutions even increased GLP-1 efficacy significantly and 
hence, Cys236, Cys329, Cys341, Cys347, Cys438, Cys458 and Cys462 appeared to be functionally 
redundant in GLP-1R. However, four Cys-Ala substitutions (Cys174-Ala, Cys226-Ala, Cys296-Ala 
and Cys403-Ala) significantly reduced GLP-1 potency (Table 1 and Figure 2). Substitution of 
Cys174 with Ala significantly reduced the potency of GLP-1 from 11 ± 3.2 pM to 66 ± 9.5 pM 
(p=0.005) (Figure 2A). Cys174 was subsequently substituted with serine, which is more similar 
to cysteine. However, the Cys174-Ser substitution significantly reduced the potency of GLP-1 
from 11 ± 3.2 pM to 79 ± 7.4 pM (p=0.001). The Cys403-Ala mutation in TM7 significantly 
reduced GLP-1 potency from 11 ± 3.2 pM to 59 ± 7.4 pM (p=0.004) (Table 1 and Figure 2D). 
It was recently shown that Cys226 and Cys296 are functionally linked through what appears to 
be a disulfide bond [38]. In the present study, Cys226-Ala showed markedly reduced GLP-1 
potency (> 1000 fold compared to wild-type GLP-1R, Table 1 and Figure 2B). Emax for GLP-1 
was not achieved within the concentration range due to low potency. The Cys296-Ala 
substitution reduced GLP-1 potency noticeably less compared to Cys226-Ala (Figure 2C). 
Substituting Cys296 with Ala reduced GLP-1 potency 10-fold compared to wild-type GLP-1R 
(p=0.02) but significantly increased GLP-1 efficacy (p=0.005) (Table 1). In conclusion, Cys236, 
Cys329, Cys341, Cys347, Cys438, Cys458 and Cys462 appear to be functionally redundant in GLP-1R, 




3.2 Development of a fully functional cysteine-deprived GLP-1R 
Based on the results of the single Cys-Ala substitutions, we constructed a cysteine-deprived 
GLP-1R called Cys1. Cys1 contained seven Cys-Ala substitutions (Cys236-Ala, Cys329-Ala, 
Cys341-Ala, Cys347-Ala, Cys438-Ala, Cys458-Ala and Cys462-Ala) (Figure 3A). Cys2, Cys3 and Cys4 
were prepared from Cys1 by introducing an additional Cys174-Ala, Cys403-Ala or Cys174-
Ala:Cys403-Ala double mutation, respectively (Figure 3A). The functional properties of the four 
cysteine-deprived GLP-1Rs are shown in Figure 3B.  
The potency and affinity of GLP-1 was similar for Cys1 compared to wild-type GLP-1R (EC50= 
11 ± 2.3 pM and IC50= 0.3 ± 0.02 nM for Cys1 compared to EC50= 9 ± 2.2 pM and IC50= 1.0 ± 
0.2 nM for wild-type GLP-1R). However, the expression level of Cys1 appeared to be reduced 
to ~ 60% of wild-type GLP-1R in transiently transfected HEK293 cells based on specific binding 
of 125I-GLP-1 (data not shown). Cys2 contained an additional Cys174-Ala substitution in ICL1, 
and Cys4 contained an additional Cys174-Ala:Cys403-Ala double mutation compared to Cys1. 
This completely abolished GLP-1-mediated cAMP production (Figure 3B). Cys3 contained an 
additional Cys403-Ala substitution in TM7 compared to Cys1, which reduced to potency of GLP-1 
noticeably (from EC50= 9 ± 2.2 pM on wild-type GLP-1R to EC50= 242 ± 81 pM on Cys3). 
Hence, seven cysteine residues (Cys236, Cys329, Cys341, Cys347, Cys438, Cys458 and Cys462) were 
dispensable in GLP-1R, and simultaneous substitution of these cysteines with alanine had no 
effect on GLP-1 binding or function.  
 
3.3 Truncation of the GLP-1R C-terminal 
We prepared a series of extensive deletions in the C-terminal tail of wild-type GLP-1R in order 
to determine the limit for truncation (Figure 4). The truncated receptors were initially 
characterized by their ability to stimulate cAMP production in response to GLP-1, and fully 
functional receptors were subsequently characterized by their ability to bind GLP-1 (Table 2 
and Figure 5). In order to confirm the results of a previous GLP-1R truncation study [34], we 
deleted the last 44 amino acids of wild-type GLP-1R. However, the 1-419 truncation mutant 
significantly reduced the potency of GLP-1 from EC50= 17 ±3.3 pM for wild-type GLP-1 to 
EC50= 106 ± 13 pM for 1-419 (p = 0.02) (Figure 5A). More extensive deletions completely 
abolished GLP-1-mediated cAMP production (Table 2). Conversely, the reduced potency of 
GLP-1 for the 1-419 truncation mutant was almost completely restored by the presence of 
Trp420, as the GLP-1-mediated responses of 1-420 and 1-421 were comparable to wild-type 
GLP-1R (Table 2). However, the specific binding of 125I-GLP-1 was dramatically reduced for the 
1-421 truncation mutant (~ 6% compared to wild-type GLP-1R, Figure 6), which suggested 
low surface expression of the receptor. The presence of Leu422 increased the specific binding to 
32%, and the presence of Leu422-His426 increased the specific binding of 125I-GLP-1 to 65% 
compared to wild-type GLP-1R (Figure 6). Despite reduced binding of 125I-GLP-1, the 1-422 
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and 1-426 truncation mutants displayed similar potency and affinity for GLP-1 compared to 
wild-type GLP-1R (Table 2 and Figure 5). Hence, Leu422 appears to mark the limit for C-
terminal truncation of wild-type GLP-1R, although this probably compromises receptor 
expression. Cys1 was subsequently truncated after Leu422 and His426 respectively, and the 
truncated receptors were characterized by their ability to bind GLP-1 and stimulate cAMP 
production in response to GLP-1 (Table 2 and Figure 5). The specific binding of 125I-GLP-1 to 
Cys11-422 and Cys11-426 was reduced to a level comparable to the specific binding of 125I-GLP-1 
to 1-422 and 1-426 (Figure 6). This reduced the potency and efficacy of GLP-1 for the Cys11-
422 mutant although the reduction did not reach statistical significance. The affinity of GLP-1 for 
the Cys11-422 mutant could not be determined due to poor definition of the top-and bottom 
plateau of the binding curve, which may in turn be a result of reduced surface expression of 
the receptor. In contrast, the potency and affinity of GLP-1 for the Cys11-426 mutant was similar 
to wild-type GLP-1R (Table 2).  
 
4. Discussion 
4.1 The importance of cysteines in the TM domain of GLP-1R 
The aim of our work was to develop a fully functional cysteine-deprived and C-terminally 
truncated GLP-1R. GLP-1R contains seventeen cysteine residues (Figure 1) of which six are 
essential for maintaining the tertiary structure of ECD [17]. The remaining eleven cysteines are 
found in the transmembrane (TM) helices, the loops and in the intracellular C-terminal tail. 
According to the existing literature, only Cys329 has been shown to be redundant [26]. We 
substituted the remaining ten cysteines with alanine (Cys174 was changed to both Ala and Ser) 
in order to determine their functional redundancy in GLP-1R. Based on the substitution of 
single cysteines, we found that six of the ten Cys-Ala substitutions had no significant negative 
effect on the GLP-1-mediated response and hence, Cys236, Cys329, Cys341, Cys347, Cys438, Cys458 
and Cys462 appeared to be functionally redundant in GLP-1R. The reduced efficacy of GLP-1 
reported previously  for the Cys438-Ala substitution [27] was not observed in this study. 
The remaining four cysteines (Cys174, Cys226, Cys296 and Cys403) significantly reduced GLP-1 
potency when changed to alanine. Cys174 resides in ICL1, distant from the putative binding site 
of GLP-1. Nevertheless, substitution of Cys174 with Ala significantly reduced the potency of 
GLP-1. This could indicate that Cys174 helps to stabilize an active conformation of the receptor. 
However, Mathi et al. previously showed that the Cys174-Ala mutation significantly reduced the 
expression level of GLP-1R [26], which correlates well with the reduced potency of GLP-1 
observed in this study. The increased efficacy of GLP-1 cannot immediately be explained based 
on these results. Cys174 was subsequently changed to serine, which is more similar to cysteine. 
However, this substitution significantly reduced the potency of GLP-1, demonstrating the 
importance of a cysteine in ICL1. The presence of a cysteine in TM7 may also be important for 
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GLP-1 function and/or expression of GLP-1R, as the Cys403-Ala mutation significantly reduced 
GLP-1 potency. 
It was recently shown that Cys226 and Cys296 are functionally linked through what appears to 
be a disulfide bond [38] similar to the disulfide bond connecting ECL1/TM3 and ECL2 in family 
A [21-23] and other family B GPCRs [24;25]. Our results confirm that Cys226 is important for 
the structural integrity of GLP-1R TM domain and/or GLP-1 binding and function. Interestingly, 
the Cys296-Ala substitution reduced GLP-1 potency noticeably less compared to Cys226-Ala. 
Hence, lack of functional coupling between ECL1 and ECL2 appears to have a more pronounced 
effect on GLP-1 function if Cys226 is replaced by Ala compared to Cys296. A similar observation 
was made recently for the rat GLP-1R [38], but the loss-of-function effect of the Cys226-Ala 
mutation was restored by additional substitution of Cys296 to Ala. The loss of GLP-1 potency 
observed for the Cys226-Ala mutant was thus explained as a result of the released, bulky Cys296 
rather than a result of an absent disulfide bond [38]. It may be that GLP-1 function is affected 
more by the putative release of Cys296 compared to the release of Cys226 because Cys296 
resides closely to the binding/activation pocket of GLP-1. In this way, the presence of a free, 
bulky cysteine in position 296 (in the Cys226-Ala mutant) would have a more significant effect 
on GLP-1 potency compared to a free Ala (in the Cys296-Ala mutant). The presence of a free 
Ala in position 296 would reduce GLP-1 function compared to wild-type GLP-1R where rotation 
of Cys296 is restricted by a disulfide bond to Cys226. This restriction may keep Cys296 away from 
the GLP-1 binding/activation pocket in the wild-type receptor, and would explain why the 
Cys296-Ala mutation reduces GLP-1 potency by 10-fold. However, a recent publication 
enhances the significance of Cys296 by showing that a Cys296-Ala substitution decreases GLP-1 
potency for the cAMP pathway by 100-fold and at the same time enhances GLP-1 signaling 
bias for phosphorylation of ERK1/2 [39]. In conclusion, the single cysteine substitutions show 
that Cys236, Cys329, Cys341, Cys347, Cys438, Cys458 and Cys462 appear to be functionally 
redundant in GLP-1R, whereas Cys174, Cys226, Cys296 and Cys403 may be required for the GLP-1-
mediated response.  
In order to investigate whether the seven redundant cysteine residues could be removed from 
GLP-1R simultaneously and whether this affected the function of Cys174 and Cys403, we 
constructed a cysteine-deprived GLP-1R called Cys1 (Figure 3A). Cys2, Cys3 and Cys4 were 
prepared from Cys1 by introducing an additional Cys174-Ala, Cys403-Ala or Cys174-Ala:Cys403-Ala 
double mutation, respectively (Figure 3A). The potency and affinity of GLP-1 was similar for 
Cys1 compared to wild-type GLP-1R, which confirmed the functional redundancy of the seven 
cysteine residues. However, changing a single cysteine in Cys1 to alanine (Cys174), completely 
abolished GLP-1-induced cAMP production (Cys2). Simultaneous substitution of Cys403 with 
alanine (Cys4) did not change to functionality of the receptor, which confirmed the importance 
of Cys174 for the structural integrity and/or activation of GLP-1R. The reduced GLP-1 potency of 
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Cys3 established that Cys403 may also be important for GLP-1 function and/or expression of 
GLP-1R. 
 
4.2 A fully functional cysteine-deprived and C-terminally truncated GLP-1R 
FRET based studies have shown that the intracellular C-terminal part of β2AR is flexible and 
unstructured [31], and several family A GPCRs have been C-terminally truncated to facilitate 
crystallization [28-30]. The distal part of GLP-1R C-terminus appears to be important for 
desensitisation and internalisation of the receptor [37], but not for G-protein-mediated 
signaling [34]. It was previously reported that GLP-1R can be truncated after Arg419 without 
affecting GLP-1 affinity or potency [34]. This study served as a starting point for the C-
terminal truncations described in this paper. However, we were not able to reproduce the 
findings of Vázquez et al., as the 1-419 truncation mutant significantly reduced GLP-1 potency. 
More extensive deletions completely abolished GLP-1-mediated cAMP production, suggesting 
that the membrane proximal part of GLP-1R C-terminal is important for expression of GLP-1R 
at the cell surface and/or receptor activation. Interestingly, biophysical studies of a peptide 
mimic of the membrane proximal part of the calcitonin receptor-like receptor (CLR) C-terminal 
indicated that this region forms a membrane-anchored α-helix similar to  helix 8 of family A 
GPCR [40]. The putative helix 8 of CLR was subsequently found to be involved in Gs-coupling 
and cell surface expression of the receptor [41]. The latter has also been shown for the 
membrane proximal part of GLP-2R C-terminal [35]. It must be noted, however, that the C-
terminal of CRFR1 is completely dispensable [42], so an eighth helix may not be present in all 
family B GPCRs. In line with the role of the membrane proximal part of the C-terminal 
described for other family B GPCRs, we observed a direct correlation between the length of the 
C-terminal and the specific binding of 125I-GLP-1. Accordingly, our results support the notion 
that the membrane proximal part of the C-terminal tail could be involved in transport of GLP-
1R to the cell surface. The reduced binding of 125I-GLP-1 did not affect the affinity or potency 
of GLP-1 for the 1-422 and 1-426 truncation mutants. Hence, Leu422 appears to mark the limit 
for C-terminal truncation of wild-type GLP-1R, although this probably compromises receptor 
expression. 
Based on the results obtained with C-terminal truncation of the wild-type GLP-1R, Cys1 was 
truncated after Leu422 and His426, respectively. As for the wild-type receptor, we observed a 
direct correlation between the length of the C-terminal and the specific binding of 125I-GLP-1. 
Interestingly, the specific binding of 125I-GLP-1 was reduced to a level comparable to 1-422 
and 1-426 in wild-type GLP-1R despite reduced specific binding/expression of the template 
receptor, Cys1 (data not shown). Hence, the specific binding of 125I-GLP-1 was comparable for 
Cys1 and for the truncated Cys11-426 mutant, indicating that Cys1 is less sensitive to C-terminal 
truncation with regards to cell surface expression. Conversely, Cys1 seems more sensitive to 
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C-terminal truncation with regards to receptor functionality, than the wild-type GLP-1R. The 
potency of GLP-1 was reduced for the Cys11-422 mutant although the specific binding of 125I-
GLP-1 was comparable to that of the 1-422 wild-type mutant. In contrast, the potency and 
affinity of GLP-1 for the Cys11-426 mutant was similar to wild-type GLP-1R, which established 
that  seven cysteines and the last 37 residues of the C-terminal tail can be removed from GLP-
1R without compromising GLP-1 binding or function. 
Conclusion- The present study describes the development of a cysteine-deprived and C-
terminally truncated GLP-1R that retains full GLP-1 potency and affinity (Cys11-426). The results 
show that seven cysteines and more than half of the C-terminal tail are not required for GLP-1 
binding or function. Presence of an eighth helix in GLP-1R has not yet been reported, but the 
results presented here indicate that the membrane proximal portion of the C-terminal tail is 
important for expression of GLP-1R at the cell surface. 
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Table 1. Functional properties of wild-type and cysteine-substituted GLP-1Rs  
All values represent mean ± SEM of three independent experiments performed in duplicates. 
The EC50 values of GLP-1 are given in pM, and GLP-1 efficacy (Emax) is given in pmol cAMP. The 
EC50 and Emax values of GLP-1 on mutant receptors were compared to those of wild-type GLP-
1R individually using the unpaired t-test. * indicates p < 0.05 and ** indicates p < 0.01. (a) 
The Emax value was calculated by Prism 5.0® (GraphPad Software, Inc.) even though the top 
plateau of the concentration-response curve was not well-defined. The top of the curve was 
fitted by obtaining the best symmetry with the lowest sum-of-squares. ND: Not detectable 
within the concentration range due to low potency. 
 
Table 2. Functional properties of wild-type and C-terminally truncated GLP-1Rs 
All values represent mean ± SEM of 2-6 independent experiments performed in duplicates. 
Agonist 125I-GLP-1 tracer was used for competition binding experiments. The EC50, Emax and 
IC50 values of GLP-1 for the mutant receptors were compared to those of wild-type GLP-1R 
individually using the unpaired t-test. * indicates p = 0.02. (a) The Emax value was calculated 
by Prism 5.0® (GraphPad Software, Inc.) even though the top plateau of the concentration-
response curve was not well-defined. The top of the curve was fitted by obtaining the best 
symmetry with the lowest sum-of-squares. ND: Not detectable, possibly due to low surface 
expression. 
 
Figure 1. Cysteine residues in GLP-1R                                                                       
Snake diagram of GLP-1R showing the position and numbering of the seventeen cysteine 
residues (white letters in black circles) in the receptor. The putative disulfide bond between 
Cys226 and Cys296 is indicated with a dashed line. The predicted signal sequence (light grey) 
[43] and putative glycosylation sites (Y) [11] are also shown. 
 
Figure 2. Concentration-response curves for cysteine-substituted GLP-1Rs with 
reduced GLP-1 potency                                                                                         
GLP-1-induced cAMP production in HEK293 cells expressing the Cys174-Ala (A), Cys226-Ala (B), 
Cys296-Ala (C) or Cys403-Ala (D) mutant GLP-1Rs. Red curves show the GLP-1-induced 
response of mutant receptors compared to that of the wild-type GLP-1R (black dashed curve). 
Data represent the average of three independent experiments for each receptor mutant. 
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Figure 3. Amino acid sequence and functional properties of four cysteine-deprived 
GLP-1Rs                                                                                                                                   
(A) Amino acid sequence of Cys1-Cys4. Cys1 contained seven Cys-Ala substitutions (white 
letters in black circles). Cys2, Cys3 and Cys4 were prepared from Cys1 by introducing an 
additional Cys174-Ala, Cys403-Ala or Cys174-Ala:Cys403-Ala double mutation, respectively (black 
letters in gray circles). (B) Stimulation of cAMP production by GLP-1 in HEK293 cells transiently 
expressing wild-type or Cys1-Cys4 GLP-1Rs. Data represent one of two independent 
experiments performed in duplicate. (C) 125I-GLP-1 displacement by GLP-1 on plasma 
membranes from HEK293 cells transiently expressing wild-type (black dashed curve) or Cys1 
GLP-1R (red curve).  Data are normalized according to 125I-GLP-1 binding and represent one of 
three independent experiments performed in duplicate. 
  
Figure 4. Snake diagram of GLP-1R C-terminal tail                                                  
Seven extensive deletions were made in the wild-type GLP-1R C-terminal tail. Arrowheads 
indicate deletion sites. 
 
Figure 5. Functional- and binding properties of C-terminally truncated GLP-1Rs       
(A) Stimulation of cAMP production by GLP-1 in HEK293 cells transiently expressing wild-type 
or truncated GLP-1Rs. Data represent 3-5 independent experiments performed in duplicate. 
(B) 125I-GLP-1 displacement by GLP-1 on plasma membranes from HEK293 cells transiently 
expressing wild-type or truncated GLP-1R.  Data are normalized according to 125I-GLP-1 
binding and represent 2-6 independent experiments performed in duplicate. 
 
Figure 6. Specific binding of 125I-GLP-1 to C-terminally truncated GLP-1Rs          
Plasma membranes from transiently transfected HEK293 cells expressing wild-type GLP-1R or 
truncated GLP-1Rs were incubated with 1 pM GLP-1 and 50 pM 125I-GLP-1 for 2 hours at 30oC. 
Nonspecific binding was determined using 1 µM GLP-1. Specific binding of 125I-GLP-1 to each of 
the truncated GLP-1Rs was compared to that of wild-type GLP-1R using the unpaired t-test. 
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Study IV – Real-time cAMP profiles of GLP-1R agonists 
A part of the Ph.D. studies included secondment to the lab of Prof. Hans Bräuner-Osborne, 
Dept. of Drug Design and Pharmacology, University of Copenhagen. The group is currently 
optimising the use of Epac-based cAMP biosensors as a tool to study GPCR pharmacology. The 
purpose of the Ph.D. work was to study the cAMP kinetics of GLP-1R upon stimulation with 
different receptor agonists. The results suggested that exendin-4 has a prolonged effect on 
GLP-1R compared to other ligands. Subsequent experiments indicated that this could be a 
result of superior enzymatic stability of exendin-4, but further investigations are required to 
confirm this. Some of the results obtained in Study IV are included in a co-authored paper that 
is currently in preparation (226). I undertook all the experimental work included in Study IV 
apart from the Luminescent Oxygen Channeling Immunoassay (LOCI), which was performed 
by Christian Rosenquist, Research Bioanalysis, Novo Nordisk A/S.   
Introduction to cAMP biosensors 
GLP-1R preferably couples to the Gs-protein (194) which leads to activation of AC and 
consequently to the formation of cAMP from ATP. Quantification of intracellular cAMP levels is a 
central technique in pharmacological characterisation of GPCRs, and numerous methods have 
been developed over the years. The functional receptor assay used to quantify cAMP levels in 
Study I, Study II and Study III (FlashPlate®, Perkin Elmer) is an immunobased assay, where a 
known amount of labelled cAMP compete with non-labelled cell-derived cAMP for a fixed 
number of binding sites (anti-cAMP antibody) (supplier’s manual). Like many other 
commercially available functional assays, the FlashPlate® assay is used to quantify the 
accumulated amount of intracellular cAMP over a fixed period (endpoint cAMP). However, over 
the past years, different FRET-based cAMP biosensors have been developed (243-245). The 
biosensors enable continuous monitoring of cAMP as it is produced and degraded (real-time 
cAMP), which offers a more accurate and sensitive approach to study GPCR activation. In 
addition, a biosensor can be tagged with a signal sequence that localises the sensor to a 
specific subcellular compartment, which in turn facilitates spatial and temporal monitoring of 
cAMP (244). The first cAMP biosensors used a fluorescent probe based on Protein kinase A 
(PKA) (245). However, in recent years, fluorescently labelled ‘Exchange protein directly 
activated by cAMP’ (Epac) has become widely used as a cAMP biosensor (245). Epac1 and 
Epac2 are two closely related guanine nucleotide exchange factors (GEFs) for the small 
GTPases Rap1 and Rap2. Epac is activated directly by cAMP, and Epac1 has one binding site 
for cAMP, whereas Epac2 has two (246;247). The first generation of Epac-based cAMP 
biosensors used full-length Epac1 fused to enhanced cyan fluorescent protein (ECFP) in the N-
terminal and Citrine in the C-terminal (244). Upon binding of cAMP, Epac changes 
conformation, which increases the distance between the fluorophores and consequently 
changes the FRET ratio. The Epac biosensor has subsequently been optimised to obtain a more 
even distribution of fluorescence in the cytoplasm. Native Epac is mainly localised in the 
nuclear membrane and mitochondria (248), which resulted in different subcellular distributions 
of the fluorescent signal using full-length Epac (244). Deletion of the first N-terminal 148 
amino acids of Epac1 yielded a cytosolic protein (248), which retained full cAMP binding 
affinity, and thus was more suitable as a cAMP biosensor than full-length Epac (249). The 
fluorophores have also been optimised since the first Epac-based biosensors were constructed 
(250), and more efficient fluorescent FRET pairs are now used to flank the cAMP binding 
domain of Epac1 (251). 
 80 
Prof. Hans Bräuner-Osborne’s group has constructed a cAMP biosensor consisting of Epac1 
(amino acids 149-881) fused N-terminally to the monomeric form of Cerulean (mCer) and C-
terminally to the monomeric form of Citrine (mCit). A detailed description of the biosensor 
construct (Epac149, Figure 16) and its characterisation can be found in (251). Cerulean is a 
brighter variant of ECFP, which has been optimised specifically for use in FRET experiments 
(250), whereas Citrine is a modified form of yellow fluorescent protein (YFP) with increased 
brightness and photostability (252). 
 
 
Figure 16. The Epac149 biosensor. Upon binding of cAMP to the Epac149 biosensor, the distance between the two 
fluorophores mCer and mCit increases, which changes the FRET signal i. e. the em474/em524 ratio is increased. The 
figure was kindly provided by Jesper M. Mathiesen, University of Copenhagen.  
Experimental Procedures 
Cell Culture and Protein Expression – HEK293 cells were maintained in Dulbecco’s modified 
Eagles medium (BioWhittaker) supplemented with 10 vol-% fetal bovine serum (FBS) and 1 
vol-% penicillin/streptomycin (100 units/ml) in 15 cm dishes. HEK293 cells were transiently 
co-transfected with 0.1, 0.5, 10 or 21 µg GLP-1R and 21 µg Epac149 DNA using the FuGENETM 
transfection reagent (Roche Applied Science). The GLP-1R construct was described previously 
(175). Cells were harvested 24 hours after transfection and the transfection efficiency was 
quantified by means of fluorescence microscopy. Cells were used in the real-time cAMP assay 
after harvesting. 
Real-time cAMP assay - Transiently transfected HEK293 cells expressing GLP-1R and Epac149 
were harvested and resuspended in assay buffer (Hank’s Buffered Salt Solution (HBSS) 
supplemented with 20 mM HEPES, 1 mM CaCl2, 1 mM MgCl2 and 0.02% Tween-20, pH 7.4) 
supplemented with 0.3 vol-% bovine serum albumin (BSA) to a cell density of ~ 700.000 
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fluorescent counts (EnVision Multilabel Reader) for high expression levels. GLP-1(7-37), 
exendin-4, glucagon, oxyntomodulin, taspoglutide and exendin-4(9-39) were diluted in assay 
buffer. Cells in assay buffer (20 µl) and ligand (20 µl) (with or without 10 µM valine pyrrolidide 
(Valpyr)) were mixed in black 384-well plates (Corning) and the resultant fluorescence of mCer 
and mCit was measured after excitation of mCer in an EnVision Multilabel Reader (Perkin 
Elmer) at room temperature. For antagonist experiments, a final concentration of 1 µM 
exendin-4(9-39) was added 5, 30 or 300 minutes after adding the cells to GLP-1. Reading of 
the plate was initiated as soon as possible after adding the cells in order to obtain the initial 
kinetics of cAMP production. The FRET ratio (em524 nm/em474 nm) was measured every 10 
minutes for at least 300 minutes (5 hours) in the presence of agonist alone or when exendin-
4(9-39) was added after 300 minutes. The FRET ratio was measured every 2 minutes for at 
least 2 hours in all other experiments containing agonist and antagonist. For illustration 
purposes, the FRET ratio was inverted (em474 nm/em524 nm), and the ratio was plotted as a 
function of time using Prism 5.0® (GraphPad Software, Inc.).  
Apparatus - EnVision Multilabel Reader (Perkin Elmer) equipped with a CFP/YFP dichroic mirror 
and the following filters (251): Excitation filter for mCer: CFP 430 (barcode 138), emission 
filter for mCer: CFP 470 (barcode 240) and emission filter for mCit: YFP 535 (barcode 274). 
LOCI – Stability of GLP-1 and exendin-4 over time was estimated by adding 1 nM ligand (100 
µl) to HEK293 cells transiently expressing GLP-1R and Epac149 in duplicates. Cells were 
resuspended in assay buffer (100 µl) to a cell density of ~ 700.000 fluorescent counts 
(EnVision Multilabel Reader). Ligand and cells were incubated for 0, 30, 60, 90, 120, 150, 200, 
250 or 300 minutes followed by centrifugation at 10.000 g for 5 minutes. The supernatant was 
frozen immediately on dry ice. Samples were analysed using LOCI. Donor beads were coated 
with streptavidin, whereas acceptor beads were conjugated with a monoclonal antibody 
specific for the C-terminus of the ligand. The second monoclonal antibody, recognizing an N-
terminus epitope, was biotinylated. The three reactants were combined with the ligand and 
formed a two-sited immuno-complex. Illumination of the complex released singlet oxygen 
atoms from the donor beads, which were channeled into the acceptor beads and triggered a 
chemiluminescence response, which was measured in an EnVision Multilabel Reader (Perkin 
Elmer).  
Results and Discussion 
cAMP profiles of high- and low potency GLP-1R agonists 
GLP-1, exendin-4, glucagon and oxyntomodulin were added to HEK293 cells transiently 
expressing GLP-1R and Epac149, and the resultant FRET ratio (em524 nm/em474 nm) was 
measured every 10 minutes for 300 minutes (5 hours). For illustration purposes, the FRET 




Figure 17. Agonist response kinetics in HEK293 cells expressing GLP-1R and Epac149. Varying 
concentrations of (A) GLP-1, (B) exendin-4, (C) glucagon and (D) oxyntomodulin elicit different cAMP profiles. Data 
represent one of three independent experiments.   
The cAMP profiles illustrated in Figure 17 show that all four agonists stimulate cAMP production 
in a dose-dependent manner. The highest concentrations of GLP-1 (1 nM and 100 pM) appear 
to activate AC immediately, whereas lower concentrations of GLP-1 increase cAMP production 
slowly. After approximately 130 minutes, the cAMP levels peak followed by a slow decrease 
(Figure 17A). Similar observations were made for exendin-4, although exendin-4-stimulated 
cAMP levels decline more slowly compared to GLP-1 (Figure 17B). As expected, oxyntomodulin 
and glucagon activate the cAMP pathway with lower potency compared to GLP-1 and exendin-
4. Interestingly, the cAMP profiles of glucagon and oxyntomodulin are very similar (Figure 17C 
and D, respectively), but different to those of GLP-1 and exendin-4. As for GLP-1 and exendin-
4, the highest concentrations of glucagon and oxyntomodulin appear to activate AC 
immediately, but lower concentrations of the two peptides also cause a rapid increase in cAMP 
levels, which peak after approximately 40 minutes followed by a rapid decrease. In order to 
rule out that the decrease in cAMP levels observed for GLP-1, glucagon and oxyntomodulin was 
a result of peptide degradation, more ligand was added to the system after 130 or 40 minutes, 





Figure 18. The effect of adding more ligand to GLP-1R expressing cells when cAMP levels start to decline. 
HEK293 cells expressing GLP-1R and Epac149 were stimulated with either (A) 10 pM GLP-1, (B) 3 pM exendin-4, (C) 
10 nM glucagon or (D) 1 nM oxyntomodulin. Similar ligand concentrations were added to the cells after 130 minutes 
for GLP-1 and exendin-4, and 40 minutes for glucagon and oxyntomodulin. Data represent one of three independent 
experiments.  
As shown in Figure 18, addition of more ligand has an effect on the cAMP production elicited by 
GLP-1, glucagon and oxyntomodulin, but not exendin-4. Hence, the cAMP profiles observed for 
GLP-1, glucagon and oxyntomodulin (Figure 17) may be affected by degradation of the ligand. 
The stability of GLP-1 and exendin-4 was subsequently examined in more detail using an in-
house LOCI, which confirmed that GLP-1 but not exendin-4 is degraded over the course of the 
assay. As shown in Figure 19, the initial concentration of GLP-1 is reduced to approximately 
30% after 300 minutes, whereas 90% of the initial concentration of exendin-4 remains after 






Figure 19. Stability of GLP-1 and exendin-4 over time. HEK293 cells transiently expressing GLP-1R and Epac149 
were incubated with 1nM GLP-1 (A) or exendin-4 (B) for 0, 30, 60, 90, 120, 150, 200, 250 or 300 minutes. The 
resultant concentrations of each of the two ligands were quantified in an in-house LOCI.   
In order to rule out the possibility that GLP-1 is cleaved by DPP-IV, I measured the cAMP 
profile of taspoglutide, which is a DPP-IV resistant GLP-1 analogue with similar potency and 
affinity for the human GLP-1R compared to GLP-1 (253). In addition, the cAMP profile of GLP-1 
was measured in the presence of 10 µM ValPyr, which is a competitive DPP-IV inhibitor (254). 
The cAMP profile of taspoglutide was similar to that of GLP-1, and DPP-IV inhibition did not 
change the cAMP profile of GLP-1 (data not shown), which strongly suggests that the decrease 
in cAMP observed after 130 minutes (Figure 17A) was not a result of DPP-IV-mediated 
cleavage of GLP-1. However, other enzymes such as neutral endopeptidase (NEP) 24.11 may 
be responsible for the reduced stability of GLP-1 compared to exendin-4. NEP 24.11 is a 
membrane-bound metallopeptidase that cleaves GLP-1, exendin-4, glucagon and 
oxyntomodulin at multiple sites (57;255-257). The rate at which NEP 24.11 hydrolyses the 
peptides is as follows: Glucagon/oxyntomodulin > GLP-1 >> exendin-4 (256), which correlates 
well with the rapid decline in glucagon- and oxyntomodulin-induced cAMP levels and a delayed 
decline for GLP-1 and in particular exendin-4. It has been demonstrated that GLP-1 is 
degraded in vitro by NEP 24.11 present in plasma membranes derived from RINm5F cells 
(256), so GLP-1, glucagon and oxyntomodulin may also be degraded by NEP 24.11 present in 
HEK293 cell membranes.  
Based on the results shown above, it seems likely that the cAMP profiles of GLP-1, exendin-4, 
glucagon and oxyntomodulin (Figure 17) reflect a difference in stability over time rather than 
different binding- and activation modes. However, I cannot rule out the possibility that the 
different cAMP kinetic profiles are a result of divergent effects on GLP-1R. One may argue that 
there is plenty of GLP-1 left after 300 minutes (the highest concentration ~ 300 pM) to elicit a 
cAMP response from GLP-1R (Figure 19A and Figure 17A). There is a striking similarity 
between the cAMP kinetics shown in Figure 17 and the potency rank order of the four peptides 
for GLP-1R (exendin-4 ≥ GLP-1 > oxyntomodulin > glucagon). Hence, the low potency 
agonists glucagon and oxyntomodulin cause a rapid increase and decrease in cAMP production, 
whereas the cAMP response induced by GLP-1 and in particular exendin-4 is slow, but 
sustained over several hours. It is tempting to speculate that there is a connection between 
the cAMP profiles and ligand binding modes and/or specific ligand-induced receptor 
conformations. Previous studies suggest that PTH receptor ligands with high affinity for a 
distinct receptor conformation elicit a prolonged cAMP response compared to ligands that 
A B
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preferably stabilise other receptor conformations (258). A similar mechanism might explain 
why glucagon and oxyntomodulin elicit a rapid, but short-lived cAMP response, which is quite 
different from the prolonged response induced by GLP-1 and exendin-4. However, further 
investigations are required to support this. Differences in ligand-induced internalisation of GLP-
1R could also affect the cAMP profiles observed in Figure 17. Hence, GLP-1 and exendin-4 may 
remain associated with GLP-1R and Gαs as the receptor internalises, whereas the low affinity of 
glucagon and oxyntomodulin could dissociate these ligands from GLP-1R upon receptor 
internalisation and in this way prevent prolonged signalling though Gαs. It has recently been 
shown that PTH1-34  remains associated with PTH-1R, Gαs and AC as the receptor is internalised, 
whereas PTH related peptide (PTHrP) does not (259). Interestingly, an Epac-based cAMP assay 
similar to the one used here, showed that PTH1-34 elicited a prolonged cAMP response 
compared to PTHrP (259). This suggests that PTH1-34-bound  PTH-1R continues to signal 
through Gαs even after the receptor is internalised (259). Based on the cAMP profiles shown in 
Figure 17, it is tempting to speculate that similar internalisation patterns are observed for GLP-
1R and high affinity ligands like GLP-1 and exendin-4. However, co-localisation of GLP-1R, 
GLP-1/exendin-4 and Gαs remains to be shown in subcellular compartments to support this 
hypothesis. 
 
GLP-1R expression on the cell surface over time 
In addition to studying the cAMP profiles of different GLP-1R agonists, I also used the real-time 
cAMP assay to study the presence of functional GLP-1Rs on the cell surface at different time 
points and different receptor expression levels using the specific GLP-1R antagonist exendin-
4(9-39). HEK293 cells were transiently co-transfected with either 0.1, 0.5, 10 or 21 µg GLP-1R 
and 21 µg Epac149 DNA (per 15 cm dish), and the cAMP profile of GLP-1 was measured as 
described above. The presence of functional GLP-1Rs on the cell surface was confirmed by 
adding 1 µM exendin-4(9-39) after 5, 30 or 300 minutes. In Study I, Study II and Study III, 
21 µg GLP-1R DNA was used for transfection, which resulted in high expression of the 
receptor. Conversely, transfection with 0.1 or 0.5 µg GLP-1R DNA is expected to cause low 
expression of the receptor. In this study, transfection with 0.1 µg GLP-1R DNA reduced to 
window of the FRET ratio dramatically (data not shown), whereas transfection with 0.5 µg GLP-
1R DNA generated a FRET window comparable to that observed at high expression levels 
(Figure 20). As evident from Figure 20, the GLP-1-induced cAMP response was antagonised by 
1 µM exendin-4(9-39) after 30 minutes at high as well as low expression levels of the receptor. 
This observation suggests that functional GLP-1Rs are present on the cell surface after 30 
minutes of stimulation with GLP-1, and that this is not merely a result of receptor 
overexpression. Similar results were obtained when 1 µM exendin-4(9-39) was added 5 
minutes after GLP-1 (data not shown). It has previously been shown that high concentrations 
of GLP-1 induce internalisation (measured as loss of surface receptor expression) of GLP-1R 
with maximal internalisation obtained after ~ 20 minutes (195). The presence of functional 
GLP-1Rs on the cell surface after 30 minutes indicates that GLP-1R may recycle back to the 
cell surface after internalisation. GLP-1R and other family B GPCRs such as GCGR and the PTH 
receptor have previously been shown to recycle back to the cell surface after internalisation 
(260-263). However, 1 nM GLP-1 may not be sufficient to induce receptor internalisation, so 
additional studies of the internalisation- and recycling patterns of GLP-1R in HEK293 cells are 
required to confirm this. It is worth noting that 1 µM exendin-4(9-39) antagonises the 
response of 1 nM GLP-1 when GLP-1R is expressed at low levels (Figure 20D), but not when 
GLP-1R is expressed at high levels (Figure 20B). Similar observations were made after 
transfection with 10 µg GLP-1R DNA (data not shown), which confirms that the high expression 
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level obtained with either 10 or 21 µg GLP-1R DNA leads to the presence of spare receptors on 
the cell surface.  
 
 
Figure 20. Agonist response kinetics in the absence or presence of a GLP-1R antagonist. HEK293 cells 
expressing high (21 µg DNA) (A & B) or low (0.5 µg DNA) (C & D) amounts of GLP-1R were stimulated with varying 
concentrations of GLP-1. Exendin-4(9-39) (ex-4(9-39)) was added after 30 minutes (B & D). Data represent one of 
three independent experiments.   
The cAMP profiles of GLP-1, exendin-4, glucagon and oxyntomodulin illustrated in Figure 17 
represent the response of GLP-1Rs expressed at a high level, and cAMP levels were measured 
continuously for 300 minutes. In order to verify that functional GLP-1Rs were still present on 
the cell surface after stimulation with GLP-1 for 300 minutes, exendin-4(9-39) was added at 
this time point (Figure 21). Figure 21 shows that the GLP-1-induced cAMP response was indeed 
antagonised by 1 µM exendin-4(9-39), which strongly suggests that functional GLP-1Rs are 
present on the cell surface after stimulation with GLP-1 for 300 minutes. This may be a result 
of receptor overexpression, but it should be noted that 1 µM exendin-4(9-39) antagonises the 
response of 1 nM GLP-1 after 300 minutes (Figure 21B), but not after 30 minutes (Figure 
20B). This could be a result of reduced surface expression of GLP-1R after 300 minutes 
compared to 30 minutes, or it may simply a result of GLP-1 degradation over time. Either way, 
functional GLP-1Rs appear to be present on the cell surface after 5 hours in this experimental 





Figure 21. Functional GLP-1Rs on the cell surface after 5 hours of stimulation with GLP-1. HEK293 cells 
expressing high (21 µg DNA) amounts of GLP-1R and Epac149 were stimulated with varying concentrations of GLP-1 
without (A) or with (B) addition of 1 µM exendin-4(9-39) (ex-4(9-39)). Exendin-4(9-39) was added after 300 
minutes. Data represent one of three independent experiments.  
Conclusion – Study IV describes the use of a FRET-based Epac biosensor to elucidate the cAMP 
kinetics of GLP-1R upon stimulation with high- and low potency receptor agonists. The results 
show a correlation between agonist potency and cAMP kinetics, as high potency agonists elicit 
a slow, but more sustained cAMP production compared to low potency agonists. Exendin-4 
appears to have a prolonged effect on GLP-1R compared to other ligands. Whether this is a 
result of superior enzymatic stability of exendin-4, differences in binding- or activation modes 
or distinct ligand-induced internalisation patterns remains to be investigated. 
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CONCLUDING REMARKS 
The overall purpose of this thesis was to investigate how GLP-1R interacts with receptor 
agonists. The hope was to gain valuable insight into receptor-ligand interactions and to identify 
domains in GLP-1R that are involved in receptor activation. Small molecule- as well as peptide 
agonists with high and low affinity for GLP-1R were included in the study, and a 
multidisciplinary approach was used to study receptor-agonist interactions. The work has 
contributed to a more detailed understanding of GLP-1R pharmacology in a number of ways: 
 
• A crystal structure elucidated the molecular details of GLP-1 binding to GLP-1R ECD, and 
confirmed that GLP-1 adopts an α-helical conformation when bound to the ECD. In addition, 
the structure indicated that the α-helix of GLP-1 may be bent around Gly22 when GLP-1 is 
bound to the ECD of GLP-1R. 
• A combination of crystallography and site-directed mutagenesis supported the existence of 
different binding modes of GLP-1 and exendin-4. In particular, the work demonstrated a 
ligand-specific effect of a Leu32-Ala mutation in the ECD of the full-length GLP-1R. Whether 
the ligand-specific effect is affected by a kink in the α-helix of GLP-1 remains to be 
investigated. 
• A cysteine-deprived and C-terminally truncated GLP-1R established that seven cysteine 
residues and more than half of the C-terminal tail are not required for GLP-1 binding or 
function.  
•  Real-time cAMP measurements indicated that exendin-4 has a prolonged effect on GLP-1R 
compared to other peptide agonists. However, additional studies are required to uncover 
the underlying mechanism of this effect. 
• Receptor domains and specific residues involved in small molecule-mediated activation of 
GLP-1R were identified. 
 
The crystal structure of GLP-1 in complex with the ECD of GLP-1R has not only clarified the 
molecular details of GLP-1 binding, it has also improved our understanding of the differential 
affinity of GLP-1 and exendin-4 for the N-terminal part of the receptor. After its release, the 
crystal structure has also been used in homology model structures of the full-length GLP-1R, 
which may in turn guide the rational design of improved therapeutic GLP-1-based analogues 
that target GLP-1R. The identification of receptor domains and residues important for small 
molecule-mediated activation of GLP-1R could also improve the design and development of 
small molecule GLP-1R agonists that are suitable for oral administration. It is obvious that 
rational drug design, regardless of whether it is applied to peptide- or small molecule ligands, 
would benefit immensely from a crystal structure of the full-length GLP-1R. The results 
obtained with the cysteine-deprived and C-terminally truncated GLP-1R may guide the design 
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